US20210393763A1 - Novel pneumococcal vaccine formulations - Google Patents
Novel pneumococcal vaccine formulations Download PDFInfo
- Publication number
- US20210393763A1 US20210393763A1 US17/460,658 US202117460658A US2021393763A1 US 20210393763 A1 US20210393763 A1 US 20210393763A1 US 202117460658 A US202117460658 A US 202117460658A US 2021393763 A1 US2021393763 A1 US 2021393763A1
- Authority
- US
- United States
- Prior art keywords
- pneumoniae
- pnco
- glpo
- antigens
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000009472 formulation Methods 0.000 title description 20
- 229940124733 pneumococcal vaccine Drugs 0.000 title description 2
- 108010054790 glycerol-3-phosphate oxidase Proteins 0.000 claims abstract description 49
- 208000015181 infectious disease Diseases 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 claims abstract description 23
- 230000028993 immune response Effects 0.000 claims abstract description 19
- 206010061372 Streptococcal infection Diseases 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims description 35
- 206010035664 Pneumonia Diseases 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- -1 porphyrin phospholipid Chemical class 0.000 claims description 16
- 239000003981 vehicle Substances 0.000 claims description 16
- 230000001681 protective effect Effects 0.000 claims description 15
- 239000010941 cobalt Substances 0.000 claims description 7
- 229910017052 cobalt Inorganic materials 0.000 claims description 7
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 33
- 230000002163 immunogen Effects 0.000 abstract description 18
- 108091007433 antigens Proteins 0.000 description 126
- 102000036639 antigens Human genes 0.000 description 124
- 239000000427 antigen Substances 0.000 description 120
- 239000013598 vector Substances 0.000 description 78
- 230000001580 bacterial effect Effects 0.000 description 70
- 229960005486 vaccine Drugs 0.000 description 49
- 241000699670 Mus sp. Species 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 39
- 206010040047 Sepsis Diseases 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 201000010099 disease Diseases 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 22
- 208000035109 Pneumococcal Infections Diseases 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 230000003053 immunization Effects 0.000 description 18
- 238000007912 intraperitoneal administration Methods 0.000 description 18
- 230000000890 antigenic effect Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- 241000712431 Influenza A virus Species 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 230000001018 virulence Effects 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 101150051832 glpO gene Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 241000194017 Streptococcus Species 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000007704 transition Effects 0.000 description 12
- 229940037003 alum Drugs 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 10
- 210000001989 nasopharynx Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 101150045804 dexB gene Proteins 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000007596 consolidation process Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 101150102467 stkP gene Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 230000001960 triggered effect Effects 0.000 description 8
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 241000130810 Streptococcus pneumoniae D39 Species 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- XJNKZTHFPGIJNS-DFTQBPQZSA-N (2r,3s,4s,5s,6s)-2-(hydroxymethyl)-6-prop-2-enoxyoxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H](OCC=C)[C@@H](O)[C@@H](O)[C@@H]1O XJNKZTHFPGIJNS-DFTQBPQZSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 229940124950 Prevnar 13 Drugs 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 101150080370 pspA gene Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000012578 cell culture reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 238000013427 histology analysis Methods 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000028744 lysogeny Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 229940049548 pneumovax Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010242 retro-orbital bleeding Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- 108700015020 ABC-type bacteriocin transporter activity proteins Proteins 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710143182 Alpha-glycerophosphate oxidase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101150078806 BCAT2 gene Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100028194 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) alp1 gene Proteins 0.000 description 1
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 1
- 102100030024 Endothelial protein C receptor Human genes 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101150001753 MPL gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 101710160102 Outer membrane protein B Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241001135902 Peanut clump virus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000187562 Rhodococcus sp. Species 0.000 description 1
- 101100243750 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) pgtE gene Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010042591 activated protein C receptor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000005955 cellular translocation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 101150018266 degP gene Proteins 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 101150007310 htrA gene Proteins 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 101150093937 lye gene Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229960005357 lysine acetate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940031960 pneumococcal polysaccharide vaccine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 101150108303 prtA gene Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Definitions
- Streptococcus pneumoniae (the pneumococcus) is regarded as a major human pathogen and the most common cause of community-acquired pneumonia (CAP), bacterial meningitis, bacteremia, and otitis media (OM).
- CAP community-acquired pneumonia
- OM otitis media
- S. pneumoniae has been implicated as an important cause of sinusitis, septic arthritis, osteomyelitis, peritonitis, and endocarditis. Regardless of clinical manifestation, infection is always preceded by colonization of the nasopharynx and greater than 95% of children will have been colonized within the first few weeks or months of life by serotypes that are sequentially replaced as more serotypes are acquired.
- pneumococcal colonization is asymptomatic, and it is only upon external triggering (via viral infection, for example) that virulent S. pneumoniae sub-populations disseminate and cause disease.
- the illnesses caused by this transition from carriage to disease result in an approximately 15-20% mortality rate in adults with an even higher rate in elderly patients.
- Pediatric cases include >20 million yearly occurrences in the U.S. and account for the majority of emergency room admissions and associated antibiotic prescriptions, accruing billions of dollars in annual socioeconomic costs. Invasive disease has a more devastating impact in resource-poor countries with an estimated one million children (11% of all deaths in children below age five) succumbing to pneumococcal infection annually.
- Prevnar® family Pfizer
- Pneumovax® Pneumovax®
- Prevnar vaccines contain capsular polysaccharides conjugated to the diphtheria CRM197 protein.
- the most recent composition is Prevnar 13, which is designed to encompass 13 of the most common invasive serotypes of S. pneumoniae and provides protection against 74-88% of invasive pneumococcal disease cases (Alicinoet et al., Minerva Med 105, 89-97 (2014), Loo et al., The Pediatric infectious disease journal 33 Suppl 2, S140-151 (2014)).
- Pneumovax is a pneumococcal polysaccharide vaccine, introduced in 1977, that since 1983 has provided protection against 23 serotypes of S. pneumoniae (PPSV23) with 56-75% efficacy overall.
- efforts with current vaccination strategies have met with incomplete success due to 1) an inability to account for and include all current and future S. pneumoniae serotypes capable of establishing nasopharyngeal residence and 2) analogous to antibiotic treatment, the complete displacement of the asymptomatic vaccine-type S. pneumoniae biofilms with non-vaccine serotypes and by organisms (such as methicillin-resistant S. aureus [MRSA] or Haemophilus influenzae ) capable of equal or greater pathologies ( FIG.
- MRSA methicillin-resistant S. aureus
- This disclosure provides vaccine compositions that can be termed as “smart vaccines” and that leverage the current understanding of disease transition from bacterial carriage to infection with the pneumococcus serving as a model organism.
- the present vaccine compositions mount an immune response specifically against disease-causing bacterial populations without affecting carriage. Aided by a delivery technology capable of multivalent surface display, which can easily be adapted to a changing clinical picture, results include enhanced (including complete) protection against the development of pneumonia and sepsis during animal challenge experiments with multiple, highly-variable, and clinically-relevant pneumococcal isolates.
- the approach thus offers a unique and dynamic treatment option easily adaptable to other commensal pathogens.
- antigens associated with biofilm-released, virulent pneumococci have been demonstrated to show challenge protection and reduction in bacterial burden of a range of clinically-relevant S. pneumoniae strains under varying disease conditions.
- the results offer a response to a globally-relevant disease and growing concerns associated with current treatment options including risks posed by emerging serotype- and niche-replacement pathogens.
- the same tools enabling the results of this work can be applied to continually identify and simultaneously deliver new antigens as a means to address the diversity and antigenic drift potential of S. pneumoniae and other pathogens that exhibit similar virulence progression.
- this disclosure provides immunogenic compositions.
- this disclosure provides vaccine compositions comprising bacterial antigens of S. pneumoniae that are expressed at relatively higher levels during virulent phase.
- the vaccine compositions may comprise PncO, GlnO or a combination of these two antigens.
- the compositions may comprise PncO, or PncO and GlpO as the only antigenic components.
- the compositions may additionally or alternatively comprise antigenic fragments of these antigens, such as those that are surface exposed.
- the compositions may additionally or alternatively comprise other antigens of S. pneumoniae or antigenic fragments of such antigens.
- the compositions may be delivered by any delivery vehicle.
- one or more antigens may be present in solution or in suitable delivery vehicles such as nanovesicle, nanoparticles, microparticles, virus, and the like.
- Nanovesicles may be liposomes. Nanovesicles may comprise porphyrin phospholipid conjugates having cobalt chelated thereto. Delivery vehicles may be biological based hybrid delivery vehicles.
- this disclosure provides a method of eliciting an immune response against streptococcal bacteria in an individual comprising administering to the individual an immunogenic composition comprising PncO, GlnO or a combination of these two antigens.
- the compositions administered to the individual may comprise only PncO and/or GlpO, or may additionally or alternatively comprise antigenic fragments of these antigens, such as fragments that are surface exposed.
- the compositions may additionally comprise other antigens of S. pneumoniae or antigenic fragments of such antigens.
- the polypeptides used in the present compositions may be isolated polypeptides.
- the immunogenic compositions may be administered to an individual at risk of getting a streptococcal infection.
- the immunogenic compositions may be administered to populations of individuals who may be at risk of streptococcal infections, and may be part of routine yearly vaccinations.
- this disclosure provides a method of identifying antigens for effective vaccine compositions against streptococcal infections, comprising identifying antigens, exclusively or preferentially expressed by strains of bacteria during the virulent phase, such as bacteria that are released by the nasopharynx mucosal biofilm during virulent phase, testing the antigens or fragments thereof, either alone or in combination with other antigens, to determine if such antigens provide protection against streptococcal infections, such as infections by S. pneumoniae.
- FIG. 1 Streptococcus pneumoniae pathogenesis outcomes and infectious disease statistics in the United States (1998-2013).
- S. pneumoniae colonizes the human nasopharynx and produces bacterial communities or biofilms with a self-produced extracellular matrix and specialized structures protective from external and host challenges. External triggers such as viral infection prompt the active release of virulent pneumococci that disseminate to secondary sites and cause disease.
- PCVs polysaccharide conjugates vaccines [PCVs], such as the Prevnar family) mediate protection by promoting clearance of bacteria prior to biofilm establishment of serotypes included in the vaccines.
- Strains are grouped into those covered by Prevnar 7 (from left, first in each set), those covered by Prevnar 13 (second (middle) in each set), and non-vaccine types (NVT; third (right) in each set).
- F Reduction in annual infection rate in children under the age of five from 1998 to 2008 relative to 1998-1999. Dashed line corresponds to division between Prevnar 7 vaccine and non-vaccine type strains in 1999-2000 (Richter et al., Emerg Infect Dis 19, 1074-1083, (2013)).
- G Reduction in annual infection rate in children under the age of five from 2008 to 2013. Dashed line corresponds to division between Prevnar 13 vaccine and non-vaccine type strains in 2008-2009 (Richter et al., Emerg Infect Dis 19, 1074-1083, (2013)).
- FIG. 2 Identification and characterization of antigens associated with biofilm-released S. pneumoniae bacteria.
- A S. pneumoniae D39 were seeded on epithelial cells, and the biofilm structure was investigated using SEM. Visible in these images are the extracellular matrix, water channels, tower formations, and the “honeycomb” structure that pneumococci form with larger biofilms.
- Mouse bacterial burden was determined of pneumococcal populations after (B) intraperitoneally injections (sepsis model) or (C) intranasal aspiration with anesthesia (pneumonia model) using broth grown (Planktonic), biofilm-associated (Biofilm), or heat-dispersed (Heat) EF3030.
- Each dot in the graphs represents an individual mouse.
- D Time to death assessment of mice inoculated with heat-released bacteria from the sepsis (B) and pneumonia (C) models. Mice that were inoculated with either planktonic or biofilm-associated bacteria did not render death in any challenge model. Mice were immunized with various antigens and challenged with heat-released EF3030 in sepsis (E and F) and pneumonia (G) models. Dotted line represents limit of detection for bacterial counts. *P ⁇ 0.05, **P ⁇ 0.01, and ***P ⁇ 0.001, compared to Planktonic and Biofilm samples (B and C) and PspA (E).
- the dots in each set from left to right represent: Blood, Liver, and Spleen.
- the dots in each set from left to right represent: Blood, and Lung.
- thick bars indicate mean.
- FIG. 3 Directed clearance of biofilm-released bacteria and protection against mouse-passaged challenge strains.
- A Bacterial burden at various anatomical sites was determined daily in unimmunized (filled circles) and GlpO+PncO immunized (open circles) mice. Mice were inoculated intranasally without anesthesia with planktonic (red) or heat-released (blue) EF3030 or D39 bacteria. Protective capabilities of GlpO+PncO immunization were further evaluated in sepsis (B) and pneumonia (C) models with established mouse-passaged pneumococcal bacteria. Dotted lines represents limit of detection for bacterial counts. For (B) and (C), for each set, the first group of dots from the left represents Sham and the second group of dots from the left represents GlpO+PncO. In B, and C, for each group of dots, thick bars indicate mean.
- FIG. 4 Bacterial dissemination and time to death assessment of mice stably colonized with pneumococci and triggered with influenza A virus (IAV).
- FIG. 5 Characterization of lipid synthesis and liposomes.
- A The high performance liquid chromatography (HPLC) of cobalt porphyrin-phospholipid (Co-PoP) and the (B) resulting mass spectrum.
- C Binding analysis for all proteins used in the study.
- D Particle diameter and
- E zeta potential of liposomes formulated with 0, 5, and 15 ⁇ g of PspA.
- FIG. 6 Optimization of immunization delivery parameters.
- PspA was formulated with alum, complete Freund's adjuvant, and Co-PoP liposomes at two concentrations and administered (A) i.p., (B) s.q., and (C) i.n. before being assessed for antibody titer or in either a sepsis or pneumonia challenge model using planktonic D39 (1 ⁇ 10 6 cells).
- Co-PoP:5 ⁇ g at Day 14 was compared to Alum:5 ⁇ g and CFA:5 ⁇ g at Day 14. In A), B), and C), under Sepsis, and Pneumonia, for each group of dots, bars indicate mean.
- FIG. 7 Challenge dosing of D39.
- A Alum
- B complete Freund's adjuvant
- FIG. 8 Characterization of biofilm-released D39 bacteria virulence and vaccine protective capabilities. Bacterial burden was determined for pneumococcal populations after (A) intraperitoneal injections (sepsis model) or (B) intranasal aspiration after anesthesia (pneumonia model). Mice were inoculated with planktonic (broth grown), biofilm-associated, or biofilm-released D39. Each dot in the graphs represents an individual mouse; an “X” represents a mouse that became moribund and required euthanasia before the end of the experiment.
- FIG. 9 Bacterial burden associated with universal protection against mouse-passaged pneumococcal challenge strains. Mice were immunized with GlpO+PncO s.q. and challenged with planktonic (A) D39, (B) A66.1, (C) WU2, and (D) TIGR4 cells in either a sepsis or pneumonia model. Each dot in the graphs represents an individual mouse; an “X” represents a mouse that became moribund and required euthanasia before the end of the experiment. Dotted line represents limit of detection for bacterial counts.
- FIG. 10 Characteristics of directed clearance of virulent released bacteria and protection against an expanded set of strains.
- A Directed clearance of biofilm-released bacteria of passively immunized mice. Bacterial burden at various anatomical sites was determined daily in unimmunized (filled circles) and GlpO+PncO passively immunized (open-circles) mice. Mice were inoculated intranasally without anesthesia with planktonic (top row) or heat-released (bottom row) EF3030. Protective capabilities of GlpO+PncO immunization was further evaluated in the sepsis (B) model using an expanded set of mouse pneumococcal strains.
- Dotted line represents limit of detection for bacterial counts. *P ⁇ 0.05, **P ⁇ 0.01, and ***P ⁇ 0.001.
- the first group of dots from left represents Sham, and the second group of dots from left represents GlpO+PncO.
- thick bars indicate mean.
- FIG. 11 Characterization and application of the hybrid vector. Comparison of antibody and challenge protection (A, B, and C) when testing with the PspA antigen located either within the hybrid vector or tested in traditional vaccine formulations with alum and complete Freund's adjuvant (CFA). Screening of individual virulent-specific antigens (D) prior to consolidating all antigens to plasmids within the hybrid vector tested within sepsis (E) and pneumonia (F) challenge assays against virulent S. pneumoniae strain D39. Vaccination was extended to other clinically-relevant S. pneumoniae strains within sepsis (G) and pneumonia (H) models. ***P ⁇ 0.001 relative to controls on associated days. For (G), and (H) in each set, the first group of dots from left represents Sham, and the second group of dots from left represents GlpO+PncO. In C, D, G, and H, for each group of dots, thick bars indicate mean.
- FIG. 12 Overview of pneumococcal disease progression and directed vaccination.
- Asymptomatic S. pneumoniae biofilm carriage is established in the nasopharynx (I) and can be triggered for virulent cellular release (II) and dissemination characterized by extended tissue burden and disease.
- Highlighting this transition is the inset graph demonstrating that only biofilm-released S. pneumoniae spread to surrounding blood and lung locations.
- the first group of dots from left represents Blood
- the second group of dots from left represents Lung.
- the antigens delivered with the hybrid vector were chosen to elicit a directed immune response to only the virulent sub-population of S. pneumoniae (III).
- FIG. 13 Directed and extended protection using the hybrid vector. Assessment of bacterial burden was conducted across anatomical sites for unimmunized (filled circles) and immunized (using the consolidated antigens; open circles) mice challenged with avirulent (planktonic; red) or virulent (biofilm-released; blue) S. pneumoniae strain EF3030. Site-specific bacterial burden and protection was also tested over time for mice colonized with S. pneumoniae strain EF3030 and triggered for virulence progression using influenza A virus (IAV) inoculation (B, C, and D). Protection assessment was then extended to 10 additional clinically-relevant S. pneumoniae strains (E). Dotted line represents limit of detection for bacterial counts; ***P ⁇ 0.001. For (B), (C), and (E) in each set, the first group of dots from left represents Sham, and the second group of dots from left represents Consolidated. In B, C, and E, for each group of dots, thick bars indicate mean.
- IAV influenza A virus
- FIG. 14 Comparative assessment of vaccine outcomes across different formulations and administration routes with PspA.
- the hybrid vector housing PspA via expression plasmid is compared to protein formulations with either alum or complete Freund's adjuvant (CFA) and tested across intraperitoneal (IP), subcutaneous (SQ), and intranasal (IN) administration routes using sepsis (A) or pneumonia (B) mouse models challenged with S. pneumoniae strain D39.
- IP intraperitoneal
- SQ subcutaneous
- IN intranasal
- A sepsis
- B intranasal mice models challenged with S. pneumoniae strain D39.
- antibody titres are compared (C).
- thick bars indicate mean.
- FIG. 15 Antibody profiles upon vaccination with the hybrid vector containing PspA. Distributions are provided at day 14 (D14; A) and 28 (D28; B) across administration routes. In the bar graphs under Weighted AbT, for A), and B), for each set, bars from left to right are IP, SQ, and IN.
- FIG. 16 Dosing and toxicity assessment of hybrid and bacterial vectors.
- Hybrid vectors expressing PspA were administered at twelve concentrations (10 1 to 10 12 ) either IP, SQ, or IN and challenged with three concentrations of D39 in a sepsis model.
- Bacterial and hybrid vectors were administered over thirteen concentrations either IP, SQ, or IN and monitored for mouse viability.
- FIG. 17 Histological IN toxicity evaluation of hybrid devices. Specifically, mice were unvaccinated (left column) or vaccinated on days 0 and 14 by IN administration of 10 13 hybrid devices containing the consolidated antigens (right column). On day 28, the mice were challenged with a sham injury (IN instillation of 50 ⁇ L normal saline), sacrificed 24 hours later by exsanguination, the lung vasculature flushed, and the lungs fixed. The hematoxylin-eosin-stained 5 ⁇ m sections above are from the right cranial lobe of the lungs. The boxes in the 1 ⁇ images represent the areas that were subsequently acquired at 10 ⁇ , 20 ⁇ , and 40 ⁇ .
- Scale bars represent 2 mm for 1 ⁇ , 200 ⁇ m for 10 ⁇ , 100 ⁇ m for 20 ⁇ , and 60 ⁇ m for 40 ⁇ . Both samples display normal histology with no evidence of tissue damage or inflammatory reaction. The bronchial and bronchiolar mucosa and alveoli are intact with typical architecture and no indication of necrosis, edema, or inflammatory infiltrate. Images represent typical findings from all lung lobes from two mice in each group.
- FIG. 18 The pLF consolidation design and organization.
- MCS multiple cloning site
- Cm R chloramphenicol resistance
- P T7 T7 promoter
- rbs ribosomal binding site
- T T7 T7 terminator.
- FIG. 19 Challenge dosing of D39.
- FIG. 20 Bacterial burden assessed for hybrid vector vaccination with the consolidated antigens against pneumococcal challenge strains that included D39 (A), A66.1 (B), WU2 (C), and TIGR4 (D) cells in either a sepsis or pneumonia model. Dotted line represents limit of detection for bacterial counts; ***P ⁇ 0.001. For (A), (B), (C), and (D) in each set, the first group of dots from left represents Sham, and the second group of dots from left represents Consolidated. For each group of dots, thick bars indicate mean.
- FIG. 21 Probability of mutations occurring in S. pneumoniae genes (glpO, pncO, dexB, and stkP) through cellular division. Probability of at least one mutation simultaneously occurring in glpO; pncO; glpO and pncO; glpO, pncO, and dexB; and glpO, pncO, dexB, and stkP over 10 8 cellular divisions (A). Critical number of cellular divisions required to achieve a 10%, 50%, and 90% probability that at least one mutation will occur in each gene (B).
- FIG. 22 Synthetic scheme for poly(beta-amino ester) D4A4-Man. Once generated, D4A4-Man was used as the coating of the hybrid vector.
- FIG. 23 Protection summary of vaccination strategies in a sepsis model.
- Various combinations of adjuvants (Alum, Fruends Adjuvant, Co-PoP containing MPLA, and Co-PoP containing CRM197) and antigens (GlpO , PncO, and GlpO+PncO) were administered across three delivery routes (SQ, IP, and IN).
- the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197.
- thick bars indicate mean.
- FIG. 24 Protection summary utilizing a D39 sepsis challenge model.
- the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197.
- thick bars indicate mean.
- thick bars indicate mean.
- FIG. 25 Protection summary utilizing a WU2 sepsis challenge model.
- the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197.
- thick bars indicate mean.
- FIG. 26 Protection summary utilizing a TIGR4 sepsis challenge model.
- the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197.
- thick bars indicate mean.
- FIG. 27 Protection summary utilizing a A66.1 sepsis challenge model.
- the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197.
- thick bars indicate mean.
- FIG. 28 Graphical representation of surface accessible regions in the PncO sequence (A) and GlpO sequence (B). Top row shows darker shaded cytoplasmic regions, the middle row shows darker shaded surface accessible regions and the bottom row shows darker shaded transmembrane regions. Amino acid numbers are from SEQ ID NO:1 for PncO (A) and from SEQ ID NO:2 for GlpO (B) corresponding to the regions are provided in the boxes.
- immune response refers to the concerted action of the cells of the immune system including one or more of lymphocytes, antigen presenting cells, phagocytic cells, granulocytes, and others that results in selective damage to, destruction of, or elimination from the animal body of invading pathogens, cells or tissues infected with pathogens.
- immunogen refers to a substance that is able to stimulate or induce a humoral antibody and/or cell-mediated immune response in a mammal. This term may be used interchangeably with “antigen” herein.
- isolated as used herein with respect to polypeptides means polypeptides that are substantially separated from other macromolecules normally associated with the polypeptide in its natural state.
- An isolated polypeptide can be completely free of other macromolecules normally associated with the polypeptide in its natural state.
- polypeptides may be at least 50, 60, 70, 80, 90, 95, or 99% pure.
- An isolated polypeptide for example, can be purified from a cell that normally expresses the polypeptide, may be synthesized, or can be produced using recombinant DNA methodology.
- polypeptide may be used interchangeably to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds.
- Short chains are generally referred to as peptides (about 30 amino acids or less), medium chains as polypeptides (from 30 to 1,000 amino acids), and longer chains as proteins.
- Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
- Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art.
- compositions comprising PncO or a fragment thereof that elicits an immune response protective against a streptococcus, such as, for example, Streptococcus pnuemoniae .
- the PncO may be any one of those produced by a Streptococcus species, including those from Streptococcus pneumoniae, Streptococcus gordonii, Streptococcus sanguinis, Streptococcus thermophilus, Streptococcus suis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus mutans, Enterococcus faecalis, Enterococcus faecium, Rhodococcus sp.
- the PncO need not be identical to the amino acid sequence of the PncO S. pneumoniae.
- Various modifications can be made to the protein sequence without altering its immunogenicity, and protective capacity of antibodies raised thereto.
- conservative substitutions may be made within the group of following amino acids 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M).
- the antigen may be from 90 to 99% identical to the sequence of PncO provided herein, wherein the antigen is able to generate protective antibodies against a streptococcus, such as, for example, Streptococcus pnuemoniae.
- PncO is available as GenBank Accession No. ABJ54598.1 for pncO (blpY) from Streptococcus pneumoniae D39. The sequence is provided below.
- the surface accessible regions in the PncO sequence are bolded above. This is also illustrated in FIG. 28 , where the top row shows dark shaded cytoplasmic regions, the middle row shows dark shaded surface accessible regions and the bottom row shows dark shaded transmembrane regions.
- the immunogenic antigen may be from 80 to 99% identical to the sequence of PncO provided herein, wherein the antigen is able to generate protective antibodies against a streptococcus , such as, for example, Streptococcus pnuemoniae .
- the PncO has at least 70% identity, preferably 80 or 85%, such as at least 90% or at least 95, 98 or 99% identity to the PncO of SEQ ID NO:1.
- GlpO The sequence of GlpO is available as GenBank Accession No. EC 1.1.3.21 from Streptococcus pneumoniae D39. The sequence is provided below.
- the surface accessible regions in the GlpO sequence are bolded above. This is also illustrated in FIG. 28B , where the top row shows darker shaded cytoplasmic regions, the middle row shows darker shaded surface accessible regions and the bottom row shows darker shaded transmembrane regions.
- the immunogenic antigen may be from 80 to 99% identical to the sequence of GlpO provided herein, wherein the antigen is able to generate protective antibodies against a streptococcus , such as, for example, Streptococcus pnuemoniae .
- the GlpO immunogenic antigen has at least 70% identity, preferably 80 or 85%, such as at least 90% identity or at least 95, 98 or 99% identity to the GlpO sequence provided herein.
- the immunogenic composition can have PncO as the only antigen, PncO and GlpO as the only antigens or it can have additional antigens.
- the immunogenic composition can comprise PncO and other Streptococcus antigens, such as antigens from S. pnuemoniae , particularly those that are at least partially or fully surface exposed.
- the compositions can have stkP and PspA.
- the composition can comprise PncO and GlpO, and/or antigenic fragments thereof, which fragments are able to generate protective antibodies against a streptococcus, such as, for example, Streptococcus pnuemoniae .
- the antigenic fragments may be isolated fragments.
- the antigenic fragments are typically 15 to 30 amino acid (and all amino acid numbers therebetween) long and will ideally comprise an epitope from the surface exposed portions of the sequences.
- the fragments may comprise amino acid sequences that contain the sequences of the surface exposed portions shown in FIG. 28 for PncO and GlpO.
- the formulation can include a carrier or excipient.
- the formulations can include an adjuvant to enhance the extent or nature of the immune reaction. Determination of the amount of the immunogenic antigen and/or the adjuvant can be in accordance with standard techniques in the pharmaceutical or veterinary arts.
- Adjuvants that may be usefully employed in the preparation of vaccines include the following: oil adjuvants, for example, Freund's complete and incomplete adjuvants, mineral salts, alum, silica, kaolin, and carbon, polynucleotides and certain natural substances of microbial origin.
- An example of an adjuvant is a non-covalent complex of alpha-lactalbumin and fatty acid.
- Fatty acids useful for making the complex include unsaturated cis C14 to C20 fatty acids. (See WO 2014/008465).
- An example of an adjuvant is monophsophryl A.
- an adjuvant is used.
- an adjuvant can be used as a 0.001 to 50 wt % solution in phosphate buffered saline, and the antigen is present in the order of micrograms to milligrams, such as about 0.0001 to about 5 wt %, such as about 0.0001 to about 1 wt %, such as about 0.0001 to about 0.05 wt %.
- the antigen can be present in an amount in the order of micrograms to milligrams, or, about 0.001 to about 20 wt %, such as about 0.01 to about 10 wt %, or about 0.05 to about 5 wt %.
- the present disclosure provides pharmaceutical preparations which comprise, consist essentially of, or consist of PncO or immunogenic fragments thereof.
- the preparations can comprise other antigens such as, for example, GlpO.
- the only antigens in the preparation are PncO and GlpO and/or immunogenic fragments thereof.
- the composition may comprise PncO and/or GlpO as the only polypeptides in the composition.
- the pharmaceutical preparations can comprise additives, such as diluent, adjuvant, excipient, or carrier.
- additives can be liquids, such as water and oils, saline, glucose or the like, and auxiliary, stabilizing, thickening, or lubricating agents, wetting or emulsifying agents, or pH buffering agents, gelling or viscosity enhancing additives, detergents and solubilizing agents (e.g., TWEEN® 20, TWEEN® 80 also referred to as polysorbate 20 or 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol), bulking substances (e.g., lactose, mannitol), flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired.
- anti-oxidants e.g., ascorbic acid, sodium metabisulfite
- preservatives e.g., Thi
- Non-aqueous solvents or vehicles can be used such as propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
- the formulations may be lyophilized and redissolved or resuspended just before use.
- the formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
- compositions can be provided as liquid preparations, suspensions, emulsions, tablets, pills, sustained-release formulations, emulsions, aerosols, sprays, or any other form suitable for introducing the compositions into a subject to generate an immune response protective against S. pneumoniae or other streptococcaciae.
- the compositions may be administered to a human or a non-human animal.
- the antigenic compositions can be administered in delivery vehicles, which can include, but are not limited to, nanoparticles, nanovesicles (such as liposomes or other lipidic structures) and biological or hybrid delivery vehicles.
- Delivery vehicles can include, but are not limited to, nanoparticles, nanovesicles (such as liposomes or other lipidic structures) and biological or hybrid delivery vehicles.
- Liposomes may comprise one or more types of phospholipids known in the art.
- Nanovesicles comprising porphyrin conjugates can be used.
- the nanovesicles comprising porphyrin conjugates may have cobalt chelated to the porphyrin moiety.
- the nanovesicles can comprise porphyrin phospholipid conjugate, phospholipid that is not conjugated to phospholipid, optionally cholesterol, and optionally PEG-phospholipid.
- the phospholipids can be any phospholipids, saturated or unsaturated, such as DOPC, DMPC and DSPC.
- Nanovesicle carrier capable of surface-orienting peptide-based antigens are useful for enhanced immune responses.
- the nanovesicles may have an in-built adjuvant component.
- a biological based delivery vehicle can also be used.
- a hybrid vector delivery vehicle described in WO2016019126 can be used.
- the hybrid vehicle can have incorporated therein an adjuvant.
- the adjuvant can be administered as a separate component in the immunogenic compositions or it can be incorporated into the delivery vehicle.
- the antigenic compositions may be used with a hybrid vector delivery vehicle.
- a hybrid vector designed to assist the intracellular delivery of antigen cargo to antigen presenting cells can be used.
- the hybrid vector can be a biological based vector.
- the combined vector allows synergistic delivery mechanisms and disparate engineering tools to influence the process of antigen transport.
- steps associated with antigen presenting cells (APC) targeting, uptake, activation, and intracellular antigen release have been designed through a combination of the two components of the hybrid device.
- hybrid vector Highlighting the dual engineering capabilities of the hybrid vector are the polymer chemistry steps used to conjugate a mannose ligand to the poly(beta-amino ester) shell of the device which aids in APC targeting and vector uptake. Similarly, expression and localization of the LyE protein to the bacterial component of the hybrid vector safely extends the dose limits of the device.
- the biological core of the vector allows the molecular biology tools associated with a facile microbe like E. coli to be used in both antigen consolidation and internal expression prior to delivery. This capability makes the normal requirement of separate bioprocesses dedicated to antigen generation and purification unnecessary and allows a “one-pot” production and delivery device for vaccine applications.
- the hybrid vector design also offers options associated with stable storage and widespread distribution; however, features related to production and access are targets of future research.
- the results illustrate the first directed application of the vector, tested in the context of pneumococcal disease.
- the hybrid vector demonstrated improved immune response metrics using a model protein antigen (PspA) when compared to traditional vaccine formulations with alum and CFA. More importantly, once the molecular biology tools of the vector were utilized to consolidate newly-identified antigens, protection was provided across a range of clinically-relevant S. pneumoniae strains and disease models.
- PspA model protein antigen
- the antigens selected for consolidation to the hybrid vector are based upon those upregulated during virulent transition, thus, the objective is to target the disease-causing subset from a greater population of colonizing and asymptomatic S. pneumoniae cells. This capability was observed across different pneumococci strains, administration routes, and in vivo conditions, including disease onset triggered by influenza. Furthermore, the effectiveness of the antigens delivered with the hybrid vector resulted in protection extended to 10 additional S. pneumoniae strains. Though not all levels of protection were the same, complete protection was observed in 11 of 15 cases, emphasizing the broad coverage potential of the consolidated antigens tested in this study.
- the final vector provides attenuation through cellular engineering of the bacterial core and via the process of polymer coating. More importantly, the vector has not provoked any toxicity upon administration unless heightened dosages are utilized. Yet, even under enhanced dosage levels, it is possible to negate toxic effects due to the biological attenuation afforded by the LyE gene, providing another level of engineering design in applying the hybrid vector.
- Consolidating virulent-specific antigens to the hybrid device also offers a smart vaccine with in-built antigen production or an in situ means of cargo generation.
- the vector offers engineering elements that range from process-level scalability and distribution to cellular-level immune response tunability with the potential to be directed at a number of challenging vaccine opportunities beyond pneumococcal disease.
- compositions can be administered to a population in general, or can be targeted to individuals who are at risk for developing Streptococcus infections such as S. pneumoniae. For example, it can be administered to any individual who is in close contact with an infected individual.
- compositions can be introduced into a subject using any suitable administration route, including but not limited to parenteral, subcutaneous, intraperitoneal, intramuscular, intravenous, mucosal, topical, intradermal, and oral administration.
- Immunization can be done by way of a single dose or it can be done by multiple doses that are spaced apart. For example, an initial administration and subsequent booster doses can be used.
- the compositions can be administered alone, or can be co-administered or sequentially administered with other prophylactic (such as, for example, other immunogenic compositions) or therapeutic compositions (such as, for example, antibiotics).
- this disclosure provides a method of preventing pneumonia in an individual comprising administering to the individual an effective amount of a composition described herein.
- This disclosure also provides a method of reducing the overall incidence of pneumonia in a population comprising administering to a plurality of individuals in the population an effective amount of compositions described herein, whereby administration of the immunogenic compositions prevents the occurrence of pneumonia in at least some of the individuals in the population such that overall incidence of pneumonia n the population is reduced.
- the method of the present disclosure provides a strategy to induce an antibody-mediated immune response against a disease-causing subset of a commensal microbial population.
- antigens associated with biofilm-released, virulent pneumococci have demonstrated unequivocal challenge protection and reduction in bacterial burden of a range of clinically-relevant S. pneumoniae strains under varying disease conditions.
- the results offer a response to a globally-relevant disease and growing concerns associated with current treatment options including risks posed by emerging serotype- and niche-replacement pathogens.
- the same tools enabling the results of this work can be applied to continually identify and simultaneously deliver new antigens as a means to address the diversity and antigenic drift potential of S. pneumoniae and other pathogens that exhibit similar virulence progression.
- the present disclosure provides a method of identifying immunogens, such as genes, RNA, proteins, immunogens, or polypeptides that can be used for vaccine compositions against pathogens colonizing the nasal cavity mucosa—generally as a biofilm.
- pathogens will include new serotypes of S. pneumoniae , other bacteria (including those commonly found in the nasopharynx and those that colonize in addition), or other microbial targets (including viruses or fungal organisms).
- the method comprises inducing release of the pathogens by applying external triggers, including viral induced release or heat triggered release etc. For example, heat triggered release can be achieved by exposure to temperatures higher than normal body temperatures.
- the biofilm release can be achieved by exposure to temperatures from 37° C. to 39° C. for about 1 to 6 hours, or more.
- the released cells can be collected and characterized.
- Specific serotypes can be identified, cultured and surface exposed proteins can be identified that are unique to the serotype, for example.
- the same analysis can identify numerous molecular antigenic targets, as introduced above that could also be valuable vaccine ingredients.
- the newly identified proteins or portions thereof can be used to determine if immunizations with these proteins or portions thereof (such as surface exposed portions) can induce immunity against a broad spectrum of S. pneumoniae and/or other microbial targets.
- the current work presents a strategy capable of providing directed protection against virulent, biofilm-released S. pneumoniae .
- the present strategy is based upon selectively targeting those pneumococci that are triggered for virulent biofilm escape in response to changes in the nasopharyngeal environment ( FIG. 1C ).
- FIG. 2A Through the combination of an in vitro biofilm model ( FIG. 2A ), which was treated with or without factors associated with virus-induced inflammation of the nasopharynx, and transcriptional analysis of the bacterial populations comprising this model, antigens were identified that were specifically upregulated in biofilm-released pneumococci which demonstrated increased virulence.
- S. pneumoniae is a human pathogen that, with the exception of a few strains, cannot cause invasive disease in mice.
- the biofilm model was used to condition a clinical isolate of S. pneumoniae (EF3030, serotype 19F), that is cleared from the bloodstream of mice when grown in broth, to become lethally infectious.
- EF3030 cells released from biofilms by increased temperature (38.5° C., mimicking fever) induced septicemia and death in mice and thus offered a clinically-relevant surrogate model of human pneumococcal disease ( FIGS. 2B-D ).
- Planktonic, broth grown EF3030 pneumococci or those mechanically isolated from biofilms had no such virulence.
- Initial protection was then investigated by immunizing with a range of promising new antigen targets (Table 1) selected on the basis of 1) conserved sequence homology across all S. pneumoniae strains (thus, offering broad coverage potential) and, critically, 2) specific prominence in the virulent, biofilm-released bacterial population compared with the asymptomatic biofilm population.
- antigen targets up-regulated in biofilm-released pneumococci were prepared as recombinant proteins and tested for protection relative to the established S. pneumoniae surface protein antigen (PspA), which is also up-regulated during virulence transition ( FIG. 2E ).
- PspA S. pneumoniae surface protein antigen
- a bacterial challenge dosage was chosen that resulted in incomplete protection with PspA vaccination.
- GlpO an ⁇ -glycerophosphate oxidase
- PncO a bacteriocin ABC transporter transmembrane protein
- the technology is well-aligned with the antigen discovery and production techniques offered by the aforementioned biofilm model and well-established recombinant protein production. Therefore, we adopted the technology here in the delivery and assessment of GlpO and PncO. Looking forward, the Co-PoP delivery platform offers even more potential in the way of unprecedented valency of antigens discovered (i.e., the surface localization and presentation of 100s of additional protein or peptide antigens) and emphasizes the point here that even if relevant antigens are identified, their ultimate potency may not be realized unless effective delivery methods are employed.
- mice Across different anatomical locations representative of bacterial colonization (nasopharynx) and displacement (nasopharynx lavage), disseminating pneumonia (lung), and invasive septicemia (blood), vaccinated and non-vaccinated mice were challenged with less virulent (planktonic) and virulent (biofilm-released) S. pneumoniae and bacterial clearance monitored over time. In the absence of an external stimulus (e.g., viral infection), mice will remain colonized with planktonic D39 or EF3030 for 1 to 3 weeks without infection of the lower respiratory tract or the development of bacteremia.
- an external stimulus e.g., viral infection
- biofilm-released bacteria will demonstrate a similar colonization pattern as compared to avirulent bacteria but will also have the propensity to disseminate into secondary anatomical sites and cause disease.
- planktonic EF3030 and D39 cells provided a clearance baseline to compare reduced bacterial loads using virulent challenge. Clearance of biofilm-released bacteria was only mediated in vaccinated mice; whereas, the bacterial load was significantly increased and lethal in non-vaccinated mice ( FIG. 3A ). Interestingly, the rate of clearance of planktonic bacteria was unchanged despite vaccination. Thus, the data further support a directed vaccination strategy using GlpO and PncO.
- the antigenic drift potential of S. pneumoniae emphasizes the need for any new antigens to be general and effective across a wide range of challenge strains (Table 2).
- the new antigens were tested in mice infected with a range of S. pneumoniae strains chosen for their notable difficulty to protect against and the variability between strains with regard to serotype and genetic background. Complete protection was provided for both sepsis and pneumonia challenge models ( FIGS. 3B &C; FIGS. 8&9 ).
- Ten additional strains were tested in protection experiments with average time to death ranging from 12-21 days as opposed to ⁇ 3 days for controls ( FIG. 10 ).
- Bacterial and cell culture media and reagents were purchased from Fisher Chemical and Sigma-Aldrich (St. Louis, Mo.). Chemically defined bacterial growth medium (CDM) was obtained from JRH Biosciences, Lexera, Kans. Sheep blood was purchased from Hemostat Laboratories (Dixon, Calif.). All remaining reagents were purchased from Sigma-Aldrich.
- CDM chemically defined bacterial growth medium
- Glycerol stocks were then used to start overnight 3 mL LB cultures incubated at 37° C. with shaking and used to inoculate (1% v/v) 1 L of terrific broth, which was then grown to a concentration of 0.4-0.6 OD 600 under the same culture conditions. IPTG induction (100 ⁇ M) occurred at this point prior to continued culture overnight at 22° C. After clarification by centrifugation, cells were resuspended in Buffer A (50 mM Na 2 PO 4 , 500 mM NaCl, and 10% glycerol) and lysed via French press.
- Buffer A 50 mM Na 2 PO 4 , 500 mM NaCl, and 10% glycerol
- the resulting lysate was clarified by centrifugation and the resulting lysate supernatant clarified further via ultracentrifugation at 142,000 ⁇ g (RFC) for 45 minutes. Lysate collected was confirmed by SDS-PAGE at this stage prior to column purification.
- Antigen protein products were then purified by passing lysate supernatant through a fast protein liquid chromatography column (GE Healthcare HisTrap HP, 1 ⁇ 1 mL) using 2% Buffer B (50 mM Na 2 PO 4 , 500 mM NaCl, 10% glycerol, and 250 mM imidazole) and 98% Buffer A as the mobile phase.
- Buffer B 50 mM Na 2 PO 4 , 500 mM NaCl, 10% glycerol, and 250 mM imidazole
- Buffer A Buffer B
- the protein was eluted with 100% Buffer B, and a UV absorbance of 280 nm was used to detect the fractions containing protein in the elution. Those fractions were pooled and protein content characterized by SDS-PAGE and quantified by PierceTM Micro BCATM Protein Assay assessment.
- Co-PoP liposomal carrier vectors were generated as described previously (Shao et al., Nat Chem 7, 438-446, (2015)). Each injection dose contained 25 ⁇ g monophosphoryl lipid A (MPLA) in liposomes comprising DOPC:cholesterol:MPLA:Co-PoP at a molar ratio of 50:30:5:5. After dissolving liposomes in chloroform in a test tube, the solvent was evaporated and the film was further dried under vacuum overnight. Liposomes were then rehydrated with phosphate buffered saline (PBS) and sonicated.
- MPLA monophosphoryl lipid A
- FIGS. 5-7 summarize liposomal carrier characterization and immunization optimization with model antigen PspA.
- mice Outbred 6-week-old female CD-1 mice (Harlan Laboratories, Indianapolis, Ind.) were used in immunization experiments. Mice were immunized by intraperitoneal injection (i.p.; 200 ⁇ L), subcutaneous injection (s.q.; 200 ⁇ L), and intranasal aspiration (40 ⁇ L). Final antigen (Table 1) doses ranged from 5 to 15 ⁇ g in either naked or liposomal format. When combined, PncO and GlpO (Table 3) were administered at 15 ⁇ g each. After 14 days, mice were boosted with the same formulations. At day 14 and day 28, serum samples were collected from the mice by retro-orbital bleeding. For passive immunizations, respective sera were diluted ten times and administered via i.p. injection (200 ⁇ L).
- Bacterial strains used in this study are listed in Table 2 and were initially grown on Todd-Hewitt agar plates supplemented with 0.5% yeast extract and 5% sheep blood and incubated overnight at 37° C. Single colonies were used to inoculate 5 mL Todd-Hewitt broth containing 0.5% yeast extract and incubated at 37° C. to an OD 600 of 0.6. At this point, bacteria were used for challenge studies after washing one time with and resuspending in PBS.
- NCI-H292 epithelial cells were cultured in RPMI-1640 medium in T75 flasks at 37° C. and 5% CO 2 . After reaching 100% confluency, H292 cells were prefixed in 4% buffered paraformaldehyde at 34° C. for 48 hours followed by three washes with PBS. CDM-grown pneumococci were then seeded onto fixed H292 cells with change of media occurring every 12 hours. Formed biofilms were exposed to heat (38.5° C.) for 4 hours and released cells were then collected by centrifugation, washed and resuspended in PBS, and quantified by OD 600 measurement. Biofilm associated cells were disrupted by gentle pipetting, collected by centrifugation, washed and resuspended in PBS, and quantified by OD 600 measurement.
- Biofilms grown in vitro for 48 hours were fixed using 2.5% glutaraldehyde, 0.075% ruthenium red, and 0.075 M lysine acetate in 0.1 M sodium cacodylate buffer (pH 7.2) for 1 h at 22° C. This procedure has been shown to retain carbohydrate structures and improve preservation of biofilm morphology. Samples were washed three times without shaking for 15 min at 22° C. in 0.075% ruthenium red in 0.2 M sodium cacodylate buffer and were then dehydrated with a graded series of ethanol solutions (10, 30, 50, 75, 95, and 100%) at 22° C., with 15 min used for each step.
- Samples were exchanged into 100% hexamethyldisilazane and allowed to air dry before being mounted onto stubs, carbon coated, and analyzed using an SU70 scanning electron microscope at an acceleration voltage of 5.0 kV (available through the South Campus Instrumentation Center, University at Buffalo, Buffalo, N.Y.).
- mice were administered i.p. or i.n. (with isoflurane), respectively, with 1 ⁇ 10 4 to 1 ⁇ 10 6 CFU of pneumococci strains (Table 2).
- mice were administered 1 ⁇ 10 6 CFU bacteria i.n. without isoflurane.
- pneumococci colonization was followed by intranasal inoculation with 40 plaque forming units of IAV.
- IAV strain A/PR8/34 H3N2 (ATCC VR-777) was used, and titers were determined by plaque assays. Mice were monitored every four hours for signs of morbidity (huddling, ruffled fur, lethargy, and abdominal surface temperature). Mice found to be moribund were euthanized via CO 2 asphyxiation and cervical dislocation.
- mice were euthanized (as described above) and a combination of nasopharynx tissue, nasopharyngeal lavage fluid, lung, liver, spleen, and blood samples was collected and bacterial burden determined as described. Briefly, tissue and organ homogenate, lavage fluid, and blood were sonicated to ensure dissociation of bacterial aggregates and then serially diluted on tryptic soy and 5% blood agar plates prior to enumeration. Tissue burden data and associated challenge data are presented in FIGS. 8 and 9 .
- an enzyme-linked immunosorbent assay was performed by coating a 96-well Costar high binding polystyrene plate with 10 ⁇ g/mL PspA in tris-buffered saline (TBS) at 4° C. overnight. The plate was blocked with 3% BSA in TBS-Tween 20 (TBS-T) for one hour at 22° C. Sera was diluted into TBS-T in ratios of 1:1,000, 1:5,000, 1:7,500 and 1:10,000 and added to the plate. The plates were then incubated at 37° C. with mild agitation for three hours.
- the secondary antibody Anti-Mouse IgG, IgA, IgM (H+L) Highly X-Adsorbed-Biotin
- Streptavidin was added to each well in a 1:1,000 ratio and allowed to shake for 30 minutes.
- the signal was developed with p-nitrophenyl phosphate and the reaction was quenched using 0.75 M NaOH.
- the signal was detected using a plate reader spectrophotometer at an absorbance of 405 nm.
- FIGS. 1D , F, and G were obtained from the CDC's Active Bacterial Core Surveillance (ABC) for Streptococcus pneumoniae (cdc.gov/abcs/reports-findings/surv-reports.html).
- ABSC Active Bacterial Core Surveillance
- the infection rate for infectious pneumococcal disease was obtained from the annual reports from 1998-2014 for both children under 5 and the total population.
- FIG. 1E was obtained from Table 2 in Richter, et al (2013), which provided information regarding pneumococcal strain prevalence from 1998-2011; the strain distribution for children under 5 was organized into three different groups (PCV-7, PCV-13, and NVT strains).
- FIG. 1F represents the efficacy of the PCV-7 vaccine by plotting the percent reduction in infection rate following the introduction of the vaccine.
- the baseline infection rate was determined by averaging the rates from 1998-1999.
- the efficacy of the PCV-13 vaccine ( FIG. 1G ) was demonstrated by plotting the percent reduction in infection rate using the 2008-2009 infection rates as a baseline.
- the dashed lines in FIGS. 1F and 1G correspond to the prevalence of the PCV-7 and PCV-13 strains, respectively one year prior to the introduction of the vaccines.
- new antigens associated with pneumococcal disease virulence were utilized as a basis for testing the delivery and adjuvant capabilities of a hybrid biological-biomaterial vector.
- the hybrid design provides 1) dual passive and active targeting of antigen presenting cells (APCs), 2) natural and multi-component adjuvant properties, 3) dual intracellular delivery mechanisms, and 4) a simple formulation mechanism.
- the hybrid device enables device-specific, or in situ, antigen production via the biological component of the vector. This capability eliminates the need for dedicated antigen production and purification prior to vaccination efforts while leveraging the features of the overall delivery device.
- This work features a hybrid antigen delivery vector composed of biological and biomaterial components each designed to facilitate, enhance, and direct the immune response process.
- the biological portion of the vector is a bacterial cell (nonpathogenic Escherichia coli ) that, as a result of the microbial framework, possesses natural adjuvant properties and also allows the delivery of either protein or genetic antigens.
- Coating of the bacterial core with a poly(beta-amino ester) (PBAE) covalently linked to mannose provides a combined delivery device with properties to assist antigen cargo cellular translocation.
- PBAE poly(beta-amino ester)
- the size of the overall vector allows passive targeting of phagocytic APCs programmed to engulf such particles; in addition, the vector's composition and the surface characteristics endowed by the mannosylated PBAE will engage APC receptors and enhance uptake upon vector administration.
- the biomaterial and biological components can also be designed to facilitate endosomal escape and cytosolic trafficking post-phagocytosis.
- the bacterial core of the vector allows antigen cargo to be delivered as protein, nucleic acid, or both.
- the hybrid vector provides the added capability of “in situ” antigen production that can be coupled to the delivery features of the device. Combined, the vector offers a broad array of engineering opportunities meant to improve vaccine production (via rapid and scalable means of component generation, in situ antigen provision, and simple hybrid formulation) and potency (via the innate design and diverse engineering tools, i.e., polymer chemistry and molecular biology).
- Dosing levels of the hybrid vector containing PspA were also assessed and optimized across administration routes and in response to S. pneumoniae sepsis challenge using a D39 strain ( FIG. 16 ).
- D39 was selected because of its notable virulence profile and acceptance as one of the harshest preclinical challenge strains.
- Increasing the challenge inocula of S. pneumoniae can be countered with increasing hybrid vector vaccination dosages ( FIG. 16A ); however, particularly aggressive challenge levels (10 6 S. pneumoniae cells) require a vaccination dose of ⁇ 10 10 hybrid devices to mediate full protection. Due to the bacterial content of the hybrid vector, it is important to assess such enhanced dosage levels for associated toxicity. Across administration routes, toxicity was not observed until ⁇ 10 13 hybrid vectors were administered ( FIG. 16B ).
- the design of the hybrid vector allows both the chemical and biological aspects of the device to extend dosing level safety.
- the vector's polymer coating and the inclusion of a lysis E (LyE) gene provide alternative mechanisms of attenuation.
- LyE the membrane perforative activity of this protein affords safety of up to 10 20 dose levels for the resulting hybrid device (FIG. 16 B).
- histology was performed with 10 13 hybrid devices. This administration dose was selected as a result of being the highest delivery load with no associated toxicity.
- no tissue damage was observed via histological analysis as compared to the untreated control ( FIG. 17 ).
- the hybrid vector was then used to screen several antigen candidates selected due to enhanced expression during S. pneumoniae virulence transition during the course of pneumococcal disease progression (Table 4).
- the antigens would serve as the basis of a “smart vaccine” capable of directing a subsequent immune response to only a virulent sub-set of S. pneumoniae cells ( FIG. 12 ).
- FIG. 11D presents the degree of protection provided by antigen candidates StkP, DexB, GlpO, and PncO relative to PspA, with each individually delivered via the hybrid vector. Though individual protection varied by antigen, the design parameters of the hybrid vector allowed consolidated testing of all the candidates.
- a two expression plasmid system (pCJ10 and pLF; Tables 1&5 and FIG. 18 ) was utilized to enable the vector-based in situ production of the antigen products while leveraging the delivery capabilities of the hybrid device.
- pCJ10 and pLF a two expression plasmid system
- Tables 1&5 and FIG. 18 a two expression plasmid system
- complete protection was provided against the S. pneumoniae challenge strain D39 in both sepsis and pneumonia mouse models ( FIGS. 11E &F).
- the directed nature of the vaccination strategy was tested first by comparing vaccinated and non-vaccinated mice subjects with avirulent and virulent S. pneumoniae strains ( FIG. 13A ).
- S. pneumoniae strain EF3030 was used due to planktonic (or broth cultured) cells demonstrating an avirulent phenotype; whereas, those cells released from in vitro or in vivo biofilms are virulent and cause disease ( FIG. 12 ).
- the avirulent strains are cleared either with or without vaccination; whereas, only vaccinated mice are capable of demonstrating virulent bacterial clearance over time. This effect is further tested in the context of S.
- the consolidated aspect of the vaccine formulation also offers extended protection. Namely, the conserved nature of the individual antigens (Table 4), when presented in combination, provides the potential to cover a broad range of S. pneumoniae strains (Table 2). Extended protection was thus tested against a series of 10 additional S. pneumoniae strains with protection enhancement observed in all cases and complete protection provided in six cases ( FIG. 13E ).
- a hybrid biological-biomaterial vector was tested in the delivery of virulent-specific antigens targeting pneumococcal disease progression. Success was assessed by mouse model immune response outcomes that included balanced antibody profiles, a directed targeting of virulent S. pneumoniae cells, reduced bacterial dissemination and tissue burden, and challenge protection.
- the hybrid vector allowed innate (or in situ) maintenance, consolidation, and production of the antigens in addition to other features that span vaccine production and enhanced delivery capability.
- Bacterial and cell culture media and reagents were purchased from Fisher Chemical and Sigma-Aldrich (St. Louis, Mo.). Chemically defined bacterial growth medium (CDM) was obtained from JRH Biosciences, Lexera, Kans. Sheep blood was purchased from Hemostat Laboratories (Dixon, Calif.). Monomers were purchased from Sigma-Aldrich (St. Louis, Mo.) and TCI (Portland, Oreg.). Acetone (HPLC), chloroform (HPLC), n-hexadecane (99%), DMF (HPLC), and DMSO ( ⁇ 99.7%) were purchased from Fisher Chemical. Phosphate buffered saline (PBS) was purchased from Life Technologies (Grand Island, N.Y.). All remaining chemicals and reagents were purchased from Sigma-Aldrich.
- CDM chemically defined bacterial growth medium
- Monomers were purchased from Sigma-Aldrich (St. Louis, Mo.) and TCI (Portland, Ore
- step 1 allyl- ⁇ -D-mannopyranoside (ADM) was synthesized by dissolving 3 g of D-(+)-mannose and 18 mg p-TsCl in allyl alcohol (20 mL) at 90° C. under reflux for 24 h. The resulting reaction solution was concentrated by vacuum distillation at 35° C.
- step 2 acrylate-terminated D4A4 was synthesized in DMSO at a 1:1.2 amine/diacrylate molar ratio for 5 days at 60° C. with continuous stirring at 1,000 rpm.
- acrylate-terminated polymers were purified by dialysis followed by evaporation under vacuum. Dialysis procedures were conducted against acetone using molecular porous membrane tubing (Spectra/Por Dialysis Membrane, Spectrum Laboratories Inc.) with an approximate molecular weight cut-off at 3,500 Da.
- step 3 acrylate-terminated D4A4 was reacted with excess ethylenediamine to amine-cap the terminal ends (D4A4-EDA). Specifically, acrylate-terminated D4A4 was dissolved in DMSO at 167 mg/mL and reacted with 5 M ethylenediamine (in DMSO) at room temperature for 24 h.
- D4A4-EDA was purified by dialysis followed by evaporation under vacuum. In the last step, D4A4-EDA was reacted with ADM at a 1:2 molar ratio in DMSO at 90° C. for 24 h and then purified via dialysis. Structure and purity of D4A4-Man were confirmed using 1 H NMR spectroscopy.
- Antigen genes were amplified from the genomic DNA of S. pneumoniae strains using primers summarized in Table S2. Each PCR product was cloned into pET expression plasmids using the flanking restriction sites indicated (designed within the primers). Constructs were verified by colony PCR and restriction digest analysis and were then chemically transformed into the BL21(DE3) E. coli cell line (Novagen). Resulting single-colony transformants were cultured in 3 mL lysogeny broth (LB) at 37° C. with shaking prior to 15% glycerol stock storage at ⁇ 80° C. Plasmid selection antibiotics were used as needed during bacterial culture within LB medium.
- LB lysogeny broth
- pCJ10 was used in conjunction with a plasmid containing pspA, dexB, stkP, and glpO.
- the consolidated plasmid was assembled by sub-cloning each respective gene into a pACYCDuet-1 plasmid ( FIG. 18 and Table 5).
- pLF the restriction enzymes/sites were utilized for the corresponding multiple cloning sites (MCSs) within pACYCDuet-1. Plasmids were chemically transformed into E. coli strain BL21(DE3) (as the basis for hybrid device preparation) and resulting transformants prepared and stored as glycerol stocks.
- Bacterial and hybrid vectors were prepared from bacterial cultures inoculated at 2% (vol/vol) from overnight starter cultures. Following incubation at 37° C. with shaking until 0.4-0.5 OD 600 , samples were induced with 0.1 mM IPTG at 30° C. for 3 h. Bacterial vectors were then washed once and standardized to 0.5 OD 600 in PBS; whereas, bacteria to be used in hybrid vector formation were washed once and standardized to 1.0 OD 600 in 25 mM NaOAc (pH 5.15).
- Polymer was dissolved in chloroform, desiccated, and resuspended at 1 mg/mL in 25 mM NaOAc (pH 5.15) before being added in an equal volume to bacteria and mixed by vortexing on setting 5 (Analog Vortex Mixer; Fisher Scientific) for 10 s. Polymer/bacteria self-assembly was allowed to continue for 15 min, and devices were then diluted in PBS.
- mice Outbred 6-week-old female CD-1 mice (Harlan Laboratories, Indianapolis, Ind.) were used in immunization experiments. Mice were immunized by IP injection (200 ⁇ L), SQ injection (200 ⁇ L), and IN aspiration (40 ⁇ L) using isoflurane; unless indicated otherwise, 10 7 hybrid vectors were used in vaccination experiments. Immunization of controls included sham (PBS; all samples were prepared in PBS as the background solution); PspA plus alum; and PspA plus complete Freund's adjuvant (CFA), which was replaced with Incomplete Freund's Adjuvant (IFA) during booster immunizations. After 14 days, mice were boosted with the same formulations except in the case of the CFA adjuvant as noted above. At days 14 and 21, samples were collected by retro-orbital bleeding and clarified by centrifugation to collect serum.
- CFA Incomplete Freund's Adjuvant
- S. pneumoniae Bacterial Preparation and Biofilm Release S. pneumoniae strains used in this study are listed in Table 6 and were initially grown on Todd-Hewitt agar plates supplemented with 0.5% yeast extract and 5% sheep blood and incubated overnight at 37° C. Single colonies were used to inoculate 5 mL Todd-Hewitt broth containing 0.5% yeast extract and incubated at 37° C. to an OD 600 of 0.6. At this point, S. pneumoniae strains used for challenge studies were washed one time with and resuspending in PBS. NCI-H292 epithelial cells were cultured in RPMI-1640 medium in T75 flasks at 37° C. and 5% CO 2 .
- H292 cells were prefixed in 4% buffered paraformaldehyde at 34° C. for 48 hours followed by three washes with PBS. CDM-grown pneumococci were then seeded onto fixed H292 cells with change of media occurring every 12 hours. Formed biofilms were exposed to heat (38.5° C.) for 4 hours and released cells were then collected by centrifugation, washed and resuspended in PBS, and quantified by OD 600 measurement.
- Strains presented in Table 6 are a mix of mouse-passaged strains, which directly confer virulence upon culture and administration, and clinical isolates, which usually do not cause disease upon direct administration and require heat release from the in vitro biofilm model (detailed directly above) to render a virulent phenotype.
- mice were administered IP or IN (with isoflurane), respectively, with 1 ⁇ 10 4 to 1 ⁇ 10 10 CFU of pneumococci strains (Table 6).
- mice were administered 1 ⁇ 10 6 CFU bacteria IN without isoflurane.
- pneumococci colonization was followed by intranasal inoculation with 40 plaque forming units of IAV.
- a mouse-adapted IAV strain A/PR/8/34 (H1N1) was used, and titers were determined by plaque assays. Mice were monitored every four hours for signs of morbidity (huddling, ruffled fur, lethargy, and abdominal surface temperature). Mice found to be moribund were euthanized via CO 2 asphyxiation and cervical dislocation.
- mice were euthanized (as described above) and a combination of nasopharynx tissue, nasopharyngeal lavage fluid, lung, liver, spleen, and blood samples was collected and bacterial burden determined. Briefly, tissue and organ homogenate, lavage fluid, and blood were homogenized to ensure dissociation of bacterial aggregates and then serially diluted on tryptic soy and 5% blood agar plates prior to enumeration.
- the lung lobes were removed, embedded in paraffin, and 5 ⁇ m tissue slices were prepared and stained with hematoxylin and eosin by standard histopathology techniques. Histology images were acquired with an Aperio ScanScope CS slide scanner (Leica Biosystems, Buffalo Grove, Ill.) using a 40 ⁇ objective lens and subsequently analyzed using Aperio ImageScope software (v.12.3 Leica Biosystems).
- an enzyme-linked immunosorbent assay was performed by coating a 96-well Costar high binding polystyrene plate with 10 ⁇ g/mL PspA in tris-buffered saline (TBS) at 4° C. overnight. The plate was blocked with 3% BSA in TBS-Tween 20 (TBS-T) for one hour at 22° C. Sera was diluted into TBS-T in ratios of 1:1,000, 1:5,000, 1:7,500 and 1:10,000 and added to the plate. The plates were then incubated at 37° C. with mild agitation for three hours.
- ELISA enzyme-linked immunosorbent assay
- the secondary antibody (Anti-Mouse IgG, IgA, IgM (H+L), IgE, Highly X-Adsorbed-Biotin) was added to the wells in a 1:1,000 ratio and agitated for two hours. Streptavidin was added to each well in a 1:1,000 ratio and allowed to shake for 30 minutes. The signal was developed with p-nitrophenyl phosphate and the reaction was quenched using 0.75 M NaOH. The signal was detected using a plate reader spectrophotometer at an absorbance of 405 nm.
- This example provides additional data describing PncO and GlpO utilized in an expanded sepsis model. Results are shown in FIGS. 23-27 .
- adjuvant components were added to the GlpO and PncO protein antigens and testing was carried out as described in the above examples. Across the adjuvants tested with GlpO and PncO, there is generally a similar trend of vaccination effectiveness (measured as protection against disease challenge).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.
Description
- This application is a continuation of U.S. application Ser. No. 16/091,032, filed on Oct. 3, 2018, which is a U.S. National Stage Application of International Application No. PCT/US2017/026060, filed on Apr. 5, 2017, which claims priority to U.S. Provisional Patent Application No. 62/318,514, filed on Apr. 5, 2016, the disclosures of which are incorporated herein by reference.
- This invention was made with government support under contract no. AI088485 awarded by the National Institutes of Health. The government has certain rights in the invention.
- Streptococcus pneumoniae (the pneumococcus) is regarded as a major human pathogen and the most common cause of community-acquired pneumonia (CAP), bacterial meningitis, bacteremia, and otitis media (OM). In addition, S. pneumoniae has been implicated as an important cause of sinusitis, septic arthritis, osteomyelitis, peritonitis, and endocarditis. Regardless of clinical manifestation, infection is always preceded by colonization of the nasopharynx and greater than 95% of children will have been colonized within the first few weeks or months of life by serotypes that are sequentially replaced as more serotypes are acquired. Interestingly, pneumococcal colonization is asymptomatic, and it is only upon external triggering (via viral infection, for example) that virulent S. pneumoniae sub-populations disseminate and cause disease. The illnesses caused by this transition from carriage to disease result in an approximately 15-20% mortality rate in adults with an even higher rate in elderly patients. Pediatric cases include >20 million yearly occurrences in the U.S. and account for the majority of emergency room admissions and associated antibiotic prescriptions, accruing billions of dollars in annual socioeconomic costs. Invasive disease has a more devastating impact in resource-poor countries with an estimated one million children (11% of all deaths in children below age five) succumbing to pneumococcal infection annually.
- Effectively treating pneumococcal disease is difficult due to multiple populations of S. pneumoniae with different characteristics, including cells localized to a colonizing biofilm and cells triggered for dissemination and disease. Antibiotic treatment options have become limited due to the emergence of antibiotic resistance. Prior to the 1990s, most S. pneumoniae strains demonstrated universal sensitivity to penicillin. However, today penicillin-resistance varies from 5-60% in various parts of the world. Of particular concern is the increase in multidrug-resistant S. pneumoniae strains, demonstrating resistance to 3+ drug classes, which attaches substantial concerns to current antibiotic regimens regarding both efficacy and continual resistance development. In addition, S. pneumoniae biofilm formation during colonization provides a barrier to effective antibiotic activity, thus, limiting complete bacterial clearance and promoting resistance development. Finally, and more importantly, even in the event of successful bacterial clearance with antibiotic treatment, there is a risk for re-colonization by potentially more dangerous serotypes or alternative pathogens (e.g., Staphylococcus aureus), which are equally adept at biofilm formation as well as effective mechanical tolerance and high biological resistance to antibiotics.
- There are currently two pneumococcal vaccine compositions on the US market: the Prevnar® family (Pfizer) and Pneumovax® (Merck). Prevnar vaccines contain capsular polysaccharides conjugated to the diphtheria CRM197 protein. The most recent composition is Prevnar 13, which is designed to encompass 13 of the most common invasive serotypes of S. pneumoniae and provides protection against 74-88% of invasive pneumococcal disease cases (Alicinoet et al., Minerva Med 105, 89-97 (2014), Loo et al., The Pediatric infectious
disease journal 33Suppl 2, S140-151 (2014)). Pneumovax is a pneumococcal polysaccharide vaccine, introduced in 1977, that since 1983 has provided protection against 23 serotypes of S. pneumoniae (PPSV23) with 56-75% efficacy overall. However, efforts with current vaccination strategies have met with incomplete success due to 1) an inability to account for and include all current and future S. pneumoniae serotypes capable of establishing nasopharyngeal residence and 2) analogous to antibiotic treatment, the complete displacement of the asymptomatic vaccine-type S. pneumoniae biofilms with non-vaccine serotypes and by organisms (such as methicillin-resistant S. aureus [MRSA] or Haemophilus influenzae) capable of equal or greater pathologies (FIG. 1B ) (Taylor et al., Clin Infect Dis 54, 1765-1773, (2012), Feldman et al., The Journal of Infection 69, 309-325, (2014), Madhi et al., Journal of Infectious Diseases 196, 1662-1666, (2007). - This disclosure provides vaccine compositions that can be termed as “smart vaccines” and that leverage the current understanding of disease transition from bacterial carriage to infection with the pneumococcus serving as a model organism. Using conserved surface proteins highly expressed during virulent transition, the present vaccine compositions mount an immune response specifically against disease-causing bacterial populations without affecting carriage. Aided by a delivery technology capable of multivalent surface display, which can easily be adapted to a changing clinical picture, results include enhanced (including complete) protection against the development of pneumonia and sepsis during animal challenge experiments with multiple, highly-variable, and clinically-relevant pneumococcal isolates. The approach thus offers a unique and dynamic treatment option easily adaptable to other commensal pathogens.
- In this disclosure, antigens associated with biofilm-released, virulent pneumococci have been demonstrated to show challenge protection and reduction in bacterial burden of a range of clinically-relevant S. pneumoniae strains under varying disease conditions. The results offer a response to a globally-relevant disease and growing concerns associated with current treatment options including risks posed by emerging serotype- and niche-replacement pathogens. Importantly, the same tools enabling the results of this work can be applied to continually identify and simultaneously deliver new antigens as a means to address the diversity and antigenic drift potential of S. pneumoniae and other pathogens that exhibit similar virulence progression.
- In one aspect, this disclosure provides immunogenic compositions. For example, this disclosure provides vaccine compositions comprising bacterial antigens of S. pneumoniae that are expressed at relatively higher levels during virulent phase. The vaccine compositions may comprise PncO, GlnO or a combination of these two antigens. The compositions may comprise PncO, or PncO and GlpO as the only antigenic components. The compositions may additionally or alternatively comprise antigenic fragments of these antigens, such as those that are surface exposed. The compositions may additionally or alternatively comprise other antigens of S. pneumoniae or antigenic fragments of such antigens. The compositions may be delivered by any delivery vehicle. For example, one or more antigens may be present in solution or in suitable delivery vehicles such as nanovesicle, nanoparticles, microparticles, virus, and the like. Nanovesicles may be liposomes. Nanovesicles may comprise porphyrin phospholipid conjugates having cobalt chelated thereto. Delivery vehicles may be biological based hybrid delivery vehicles.
- In one aspect, this disclosure provides a method of eliciting an immune response against streptococcal bacteria in an individual comprising administering to the individual an immunogenic composition comprising PncO, GlnO or a combination of these two antigens. The compositions administered to the individual, may comprise only PncO and/or GlpO, or may additionally or alternatively comprise antigenic fragments of these antigens, such as fragments that are surface exposed. The compositions may additionally comprise other antigens of S. pneumoniae or antigenic fragments of such antigens. The polypeptides used in the present compositions may be isolated polypeptides. The immunogenic compositions may be administered to an individual at risk of getting a streptococcal infection. The immunogenic compositions may be administered to populations of individuals who may be at risk of streptococcal infections, and may be part of routine yearly vaccinations.
- In one aspect, this disclosure provides a method of identifying antigens for effective vaccine compositions against streptococcal infections, comprising identifying antigens, exclusively or preferentially expressed by strains of bacteria during the virulent phase, such as bacteria that are released by the nasopharynx mucosal biofilm during virulent phase, testing the antigens or fragments thereof, either alone or in combination with other antigens, to determine if such antigens provide protection against streptococcal infections, such as infections by S. pneumoniae.
-
FIG. 1 . Streptococcus pneumoniae pathogenesis outcomes and infectious disease statistics in the United States (1998-2013). (A) S. pneumoniae colonizes the human nasopharynx and produces bacterial communities or biofilms with a self-produced extracellular matrix and specialized structures protective from external and host challenges. External triggers such as viral infection prompt the active release of virulent pneumococci that disseminate to secondary sites and cause disease. (B) Leading vaccination strategies (polysaccharide conjugates vaccines [PCVs], such as the Prevnar family) mediate protection by promoting clearance of bacteria prior to biofilm establishment of serotypes included in the vaccines. By clearing all bacteria, the niche will be replaced by non-vaccine serotypes or other bacterial species. (C) The strategy featured in this work mediates clearance of only virulent, actively biofilm-released bacteria while simultaneously maintaining the presence of the pre-existing biofilm. (D) Annual infection rate per 100,000 people for the total population and children under the age of five from 1998-2013. The first year following introduction of Prevnar 7 and 13 are marked with dotted lines. (E) Prevalence of infectious pneumococcal strains from 1999 to 2011 (Richter et al., Emerg Infect Dis 19, 1074-1083, (2013)). Strains are grouped into those covered by Prevnar 7 (from left, first in each set), those covered by Prevnar 13 (second (middle) in each set), and non-vaccine types (NVT; third (right) in each set). (F) Reduction in annual infection rate in children under the age of five from 1998 to 2008 relative to 1998-1999. Dashed line corresponds to division betweenPrevnar 7 vaccine and non-vaccine type strains in 1999-2000 (Richter et al., Emerg Infect Dis 19, 1074-1083, (2013)). (G) Reduction in annual infection rate in children under the age of five from 2008 to 2013. Dashed line corresponds to division betweenPrevnar 13 vaccine and non-vaccine type strains in 2008-2009 (Richter et al., Emerg Infect Dis 19, 1074-1083, (2013)). -
FIG. 2 . Identification and characterization of antigens associated with biofilm-released S. pneumoniae bacteria. (A) S. pneumoniae D39 were seeded on epithelial cells, and the biofilm structure was investigated using SEM. Visible in these images are the extracellular matrix, water channels, tower formations, and the “honeycomb” structure that pneumococci form with larger biofilms. Mouse bacterial burden was determined of pneumococcal populations after (B) intraperitoneally injections (sepsis model) or (C) intranasal aspiration with anesthesia (pneumonia model) using broth grown (Planktonic), biofilm-associated (Biofilm), or heat-dispersed (Heat) EF3030. Each dot in the graphs represents an individual mouse. (D) Time to death assessment of mice inoculated with heat-released bacteria from the sepsis (B) and pneumonia (C) models. Mice that were inoculated with either planktonic or biofilm-associated bacteria did not render death in any challenge model. Mice were immunized with various antigens and challenged with heat-released EF3030 in sepsis (E and F) and pneumonia (G) models. Dotted line represents limit of detection for bacterial counts. *P<0.05, **P<0.01, and ***P<0.001, compared to Planktonic and Biofilm samples (B and C) and PspA (E). In (B), the dots in each set from left to right represent: Blood, Liver, and Spleen. In (C), the dots in each set from left to right represent: Blood, and Lung. In B, C and E, for each group of dots, thick bars indicate mean. -
FIG. 3 . Directed clearance of biofilm-released bacteria and protection against mouse-passaged challenge strains. (A) Bacterial burden at various anatomical sites was determined daily in unimmunized (filled circles) and GlpO+PncO immunized (open circles) mice. Mice were inoculated intranasally without anesthesia with planktonic (red) or heat-released (blue) EF3030 or D39 bacteria. Protective capabilities of GlpO+PncO immunization were further evaluated in sepsis (B) and pneumonia (C) models with established mouse-passaged pneumococcal bacteria. Dotted lines represents limit of detection for bacterial counts. For (B) and (C), for each set, the first group of dots from the left represents Sham and the second group of dots from the left represents GlpO+PncO. In B, and C, for each group of dots, thick bars indicate mean. -
FIG. 4 . Bacterial dissemination and time to death assessment of mice stably colonized with pneumococci and triggered with influenza A virus (IAV). Bacterial burden of EF3030 or D39 in unimmunized (red) or GlpO+PncO immunized mice was measured at 1 (A) or 5 (B) days post-infection with IAV. Protective capabilities of traditional or passively GlpO+PncO immunized mice against in vivo IAV-mediated bacterial release of EF3030 (E) or D39 (F). Dotted line represents limit of detection for bacterial counts. *P<0.05, **P<0.01, ***P<0.001. For A), and B), in each set, for both EF3030 and D39, the first group of dots from left represents Sham, and the second group of dots from left represents GlpO+PncO. In A and B, for each group of dots, thick bars indicate mean. -
FIG. 5 . Characterization of lipid synthesis and liposomes. (A) The high performance liquid chromatography (HPLC) of cobalt porphyrin-phospholipid (Co-PoP) and the (B) resulting mass spectrum. (C) Binding analysis for all proteins used in the study. (D) Particle diameter and (E) zeta potential of liposomes formulated with 0, 5, and 15 μg of PspA. -
FIG. 6 . Optimization of immunization delivery parameters. PspA was formulated with alum, complete Freund's adjuvant, and Co-PoP liposomes at two concentrations and administered (A) i.p., (B) s.q., and (C) i.n. before being assessed for antibody titer or in either a sepsis or pneumonia challenge model using planktonic D39 (1×106 cells). *P<0.05, **P<0.01, and ***P<0.001, indicating significant differences between the immunization doses and time points. For example, Co-PoP:5 μg atDay 14 was compared to Alum:5 μg and CFA:5 μg atDay 14. In A), B), and C), under Sepsis, and Pneumonia, for each group of dots, bars indicate mean. -
FIG. 7 . Challenge dosing of D39. (A) Alum, (B) complete Freund's adjuvant, and (C) Co-PoP were formulated with 15 μg of PspA protein and challenged with four levels (for example, e3=1×103 cells) of planktonic D39 in a sepsis model. -
FIG. 8 . Characterization of biofilm-released D39 bacteria virulence and vaccine protective capabilities. Bacterial burden was determined for pneumococcal populations after (A) intraperitoneal injections (sepsis model) or (B) intranasal aspiration after anesthesia (pneumonia model). Mice were inoculated with planktonic (broth grown), biofilm-associated, or biofilm-released D39. Each dot in the graphs represents an individual mouse; an “X” represents a mouse that became moribund and required euthanasia before the end of the experiment. Time to death assessment of mice inoculated with heat-released bacteria from the sepsis (C) and pneumonia (D) models after immunization with either PspA or GlpO+PncO. Dotted line represents limit of detection for bacterial counts. In (A), for each set, the first group of points (both dots and crosses) from left represents Blood, the second group of points (both dots and crosses) represents Liver and the third group of points (both dots and crosses) represents Spleen. In (B), for each set, the first group of points (dots) from left represents Blood, the second group of points (dots) represents Lung. In A and B, for each group of dots, thick bars indicate mean. -
FIG. 9 . Bacterial burden associated with universal protection against mouse-passaged pneumococcal challenge strains. Mice were immunized with GlpO+PncO s.q. and challenged with planktonic (A) D39, (B) A66.1, (C) WU2, and (D) TIGR4 cells in either a sepsis or pneumonia model. Each dot in the graphs represents an individual mouse; an “X” represents a mouse that became moribund and required euthanasia before the end of the experiment. Dotted line represents limit of detection for bacterial counts. For (A), (B), (C), and (D) in each set, for both Sepsis and Pneumonia, the first group of dots from left represents Sham, and the second group of dots from left represents GlpO+PncO. For each group of dots, thick bars indicate mean. -
FIG. 10 . Characteristics of directed clearance of virulent released bacteria and protection against an expanded set of strains. (A) Directed clearance of biofilm-released bacteria of passively immunized mice. Bacterial burden at various anatomical sites was determined daily in unimmunized (filled circles) and GlpO+PncO passively immunized (open-circles) mice. Mice were inoculated intranasally without anesthesia with planktonic (top row) or heat-released (bottom row) EF3030. Protective capabilities of GlpO+PncO immunization was further evaluated in the sepsis (B) model using an expanded set of mouse pneumococcal strains. Dotted line represents limit of detection for bacterial counts. *P<0.05, **P<0.01, and ***P<0.001. For (B), in each set, the first group of dots from left represents Sham, and the second group of dots from left represents GlpO+PncO. For each group of dots, thick bars indicate mean. -
FIG. 11 . Characterization and application of the hybrid vector. Comparison of antibody and challenge protection (A, B, and C) when testing with the PspA antigen located either within the hybrid vector or tested in traditional vaccine formulations with alum and complete Freund's adjuvant (CFA). Screening of individual virulent-specific antigens (D) prior to consolidating all antigens to plasmids within the hybrid vector tested within sepsis (E) and pneumonia (F) challenge assays against virulent S. pneumoniae strain D39. Vaccination was extended to other clinically-relevant S. pneumoniae strains within sepsis (G) and pneumonia (H) models. ***P<0.001 relative to controls on associated days. For (G), and (H) in each set, the first group of dots from left represents Sham, and the second group of dots from left represents GlpO+PncO. In C, D, G, and H, for each group of dots, thick bars indicate mean. -
FIG. 12 . Overview of pneumococcal disease progression and directed vaccination. Asymptomatic S. pneumoniae biofilm carriage is established in the nasopharynx (I) and can be triggered for virulent cellular release (II) and dissemination characterized by extended tissue burden and disease. Highlighting this transition is the inset graph demonstrating that only biofilm-released S. pneumoniae spread to surrounding blood and lung locations. In the inset, for each set, the first group of dots from left represents Blood, and the second group of dots from left represents Lung. The antigens delivered with the hybrid vector were chosen to elicit a directed immune response to only the virulent sub-population of S. pneumoniae (III). -
FIG. 13 . Directed and extended protection using the hybrid vector. Assessment of bacterial burden was conducted across anatomical sites for unimmunized (filled circles) and immunized (using the consolidated antigens; open circles) mice challenged with avirulent (planktonic; red) or virulent (biofilm-released; blue) S. pneumoniae strain EF3030. Site-specific bacterial burden and protection was also tested over time for mice colonized with S. pneumoniae strain EF3030 and triggered for virulence progression using influenza A virus (IAV) inoculation (B, C, and D). Protection assessment was then extended to 10 additional clinically-relevant S. pneumoniae strains (E). Dotted line represents limit of detection for bacterial counts; ***P<0.001. For (B), (C), and (E) in each set, the first group of dots from left represents Sham, and the second group of dots from left represents Consolidated. In B, C, and E, for each group of dots, thick bars indicate mean. -
FIG. 14 . Comparative assessment of vaccine outcomes across different formulations and administration routes with PspA. The hybrid vector housing PspA (via expression plasmid) is compared to protein formulations with either alum or complete Freund's adjuvant (CFA) and tested across intraperitoneal (IP), subcutaneous (SQ), and intranasal (IN) administration routes using sepsis (A) or pneumonia (B) mouse models challenged with S. pneumoniae strain D39. Similarly, antibody titres are compared (C). ***P<0.001 relative to controls on associated days. In A, and B, for each group of dots, thick bars indicate mean. -
FIG. 15 . Antibody profiles upon vaccination with the hybrid vector containing PspA. Distributions are provided at day 14 (D14; A) and 28 (D28; B) across administration routes. In the bar graphs under Weighted AbT, for A), and B), for each set, bars from left to right are IP, SQ, and IN. -
FIG. 16 . Dosing and toxicity assessment of hybrid and bacterial vectors. (A) Hybrid vectors expressing PspA were administered at twelve concentrations (101 to 1012) either IP, SQ, or IN and challenged with three concentrations of D39 in a sepsis model. (B) Bacterial and hybrid vectors were administered over thirteen concentrations either IP, SQ, or IN and monitored for mouse viability. -
FIG. 17 . Histological IN toxicity evaluation of hybrid devices. Specifically, mice were unvaccinated (left column) or vaccinated ondays day 28, the mice were challenged with a sham injury (IN instillation of 50 μL normal saline), sacrificed 24 hours later by exsanguination, the lung vasculature flushed, and the lungs fixed. The hematoxylin-eosin-stained 5 μm sections above are from the right cranial lobe of the lungs. The boxes in the 1×images represent the areas that were subsequently acquired at 10×, 20×, and 40×. Scale bars represent 2 mm for 1×, 200 μm for 10×, 100 μm for 20×, and 60 μm for 40×. Both samples display normal histology with no evidence of tissue damage or inflammatory reaction. The bronchial and bronchiolar mucosa and alveoli are intact with typical architecture and no indication of necrosis, edema, or inflammatory infiltrate. Images represent typical findings from all lung lobes from two mice in each group. -
FIG. 18 . The pLF consolidation design and organization. MCS: multiple cloning site; CmR: chloramphenicol resistance; PT7: T7 promoter; rbs: ribosomal binding site; TT7: T7 terminator. -
FIG. 19 . Challenge dosing of D39. Hybrid vectors expressing antigens PspA, GlpO, PncO, StkP, and DexB were administered IP, SQ, or IN and challenged with four levels (for example, e7=1×107 cells) of D39 in sepsis (A) or pneumonia (B) models. -
FIG. 20 . Bacterial burden assessed for hybrid vector vaccination with the consolidated antigens against pneumococcal challenge strains that included D39 (A), A66.1 (B), WU2 (C), and TIGR4 (D) cells in either a sepsis or pneumonia model. Dotted line represents limit of detection for bacterial counts; ***P<0.001. For (A), (B), (C), and (D) in each set, the first group of dots from left represents Sham, and the second group of dots from left represents Consolidated. For each group of dots, thick bars indicate mean. -
FIG. 21 . Probability of mutations occurring in S. pneumoniae genes (glpO, pncO, dexB, and stkP) through cellular division. Probability of at least one mutation simultaneously occurring in glpO; pncO; glpO and pncO; glpO, pncO, and dexB; and glpO, pncO, dexB, and stkP over 108 cellular divisions (A). Critical number of cellular divisions required to achieve a 10%, 50%, and 90% probability that at least one mutation will occur in each gene (B). A rate of 4.8×10−4 beneficial mutations per genome per duplication and a genome size of 2.1 Mbp were used in these calculations. In (B), for each set, bars from left to right are glpO, pncO, glpO+pncO, glpO+pncO+dexB, and glpO+pncO+dexB+stkP. -
FIG. 22 . Synthetic scheme for poly(beta-amino ester) D4A4-Man. Once generated, D4A4-Man was used as the coating of the hybrid vector. -
FIG. 23 . Protection summary of vaccination strategies in a sepsis model. Various combinations of adjuvants (Alum, Fruends Adjuvant, Co-PoP containing MPLA, and Co-PoP containing CRM197) and antigens (GlpO , PncO, and GlpO+PncO) were administered across three delivery routes (SQ, IP, and IN). For each plot in this figure, the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197. For each group of dots, thick bars indicate mean. -
FIG. 24 . Protection summary utilizing a D39 sepsis challenge model. For each plot in this figure, the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197. For each group of dots, thick bars indicate mean. For each group of dots, thick bars indicate mean. -
FIG. 25 . Protection summary utilizing a WU2 sepsis challenge model. For each plot in this figure, the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197. For each group of dots, thick bars indicate mean. -
FIG. 26 . Protection summary utilizing a TIGR4 sepsis challenge model. For each plot in this figure, the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197. For each group of dots, thick bars indicate mean. -
FIG. 27 . Protection summary utilizing a A66.1 sepsis challenge model. For each plot in this figure, the dots in each set from left to right are: Protein Alone, Alum, CFA/IFA, Co-PoP:MPLA, CO-PoP:CRM197. For each group of dots, thick bars indicate mean. -
FIG. 28 . Graphical representation of surface accessible regions in the PncO sequence (A) and GlpO sequence (B). Top row shows darker shaded cytoplasmic regions, the middle row shows darker shaded surface accessible regions and the bottom row shows darker shaded transmembrane regions. Amino acid numbers are from SEQ ID NO:1 for PncO (A) and from SEQ ID NO:2 for GlpO (B) corresponding to the regions are provided in the boxes. - In this disclosure we provide a treatment approach directed at a disease progression state of a microbial population rather than the general population. Doing so offers the potential to optimize treatment and reduce unintended pathological consequences. Such an approach is provided herein in the context of pneumococcal disease, culminating in a “smart vaccine” that directs an immune response to virulent cell populations while minimizing disruption of avirulent commensal colonization.
- The term “immune response” as used herein refers to the concerted action of the cells of the immune system including one or more of lymphocytes, antigen presenting cells, phagocytic cells, granulocytes, and others that results in selective damage to, destruction of, or elimination from the animal body of invading pathogens, cells or tissues infected with pathogens.
- The term “immunogen” as used herein refers to a substance that is able to stimulate or induce a humoral antibody and/or cell-mediated immune response in a mammal. This term may be used interchangeably with “antigen” herein.
- The term “isolated” as used herein with respect to polypeptides means polypeptides that are substantially separated from other macromolecules normally associated with the polypeptide in its natural state. An isolated polypeptide can be completely free of other macromolecules normally associated with the polypeptide in its natural state. For example, polypeptides may be at least 50, 60, 70, 80, 90, 95, or 99% pure. An isolated polypeptide, for example, can be purified from a cell that normally expresses the polypeptide, may be synthesized, or can be produced using recombinant DNA methodology.
- The terms “polypeptide”, “peptide” and “protein” may be used interchangeably to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. Short chains are generally referred to as peptides (about 30 amino acids or less), medium chains as polypeptides (from 30 to 1,000 amino acids), and longer chains as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art.
- The present disclosure provides compositions comprising PncO or a fragment thereof that elicits an immune response protective against a streptococcus, such as, for example, Streptococcus pnuemoniae. The PncO may be any one of those produced by a Streptococcus species, including those from Streptococcus pneumoniae, Streptococcus gordonii, Streptococcus sanguinis, Streptococcus thermophilus, Streptococcus suis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus mutans, Enterococcus faecalis, Enterococcus faecium, Rhodococcus sp.
- The PncO need not be identical to the amino acid sequence of the PncO S. pneumoniae. Various modifications can be made to the protein sequence without altering its immunogenicity, and protective capacity of antibodies raised thereto. For example, conservative substitutions may be made within the group of following amino acids 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M). For example, the antigen may be from 90 to 99% identical to the sequence of PncO provided herein, wherein the antigen is able to generate protective antibodies against a streptococcus, such as, for example, Streptococcus pnuemoniae.
- The sequence of PncO is available as GenBank Accession No. ABJ54598.1 for pncO (blpY) from Streptococcus pneumoniae D39. The sequence is provided below.
-
SEQ ID NO: 1 MKKYQLLFKI SAVFSYLFFV FGLSQLTLIV QNYWQFSSQI GNFVWIQNIL SLLFSGVMIW ILVKTGHGYL FRIPRKKWLW YSILTVLVVV LHISFNVQTA KHVQSTAEGW NVLIGYSGTN FAELGIYVTL FFLTPLMEEL IYRGLLQHAF FKHSRFGLDL LLPSILFALP HFLSLPSLLD IFVFATFGII FAGLTRYTKS IYPSYAVHVI NNIVATFPFL LTFLHRVLG - - The surface accessible regions in the PncO sequence are bolded above. This is also illustrated in
FIG. 28 , where the top row shows dark shaded cytoplasmic regions, the middle row shows dark shaded surface accessible regions and the bottom row shows dark shaded transmembrane regions. - The immunogenic antigen may be from 80 to 99% identical to the sequence of PncO provided herein, wherein the antigen is able to generate protective antibodies against a streptococcus, such as, for example, Streptococcus pnuemoniae. In one embodiment, the PncO has at least 70% identity, preferably 80 or 85%, such as at least 90% or at least 95, 98 or 99% identity to the PncO of SEQ ID NO:1.
- The sequence of GlpO is available as GenBank Accession No. EC 1.1.3.21 from Streptococcus pneumoniae D39. The sequence is provided below.
-
SEQ ID NO: 2 MEFSKKTRELSIKKMQERTLDLLIIGGGITGAGVALQAAASGLETGLIEMQ DFAEGTSSRSTKLVHGGLRYLKQFDVEVVSDTVSERAVVQQIAPHIPKPDP MLLPVYDEDGATFSLFRLKVAMDLYDLLAGVSNTPTANKVLSKDQVLERQP NLKKEGLVGGGVYLDFRNNDARLVIENIKRANQDGALIANHVKAEGFLFDE SGKITGVVARDLLTDQVFEIKARLVINTTGPWSDKVRNLSNKGTQFSQMRP TKGVHLVVDSSKIKVSQPVYFDTGLGDGR1VIVFVLPRENKTYFGTTDTDY TGDLEHPKVTQEDVDYLLGIVNNRFPESNITIDDIESSWAGLRPLIAGNSA SDYNGGNNGTISDESFDNLIATVESYLSKEKTREDVESAVSKLESSTSEKE ILDPSAVSRGSSLDRDDNGLLTLAGGKITDYRK1VIAEGAMERVVDILKAE FDRSFKLINSKTYPVSGGELNPANVDSEIEAFAQLGVSRGLDSKEAHYLAN LYGSNAPKVFALAHSLEQAPGLSLADTLSLHYAMRNELALSPVDFLLRRTN HMLFMRDSLDSIVEPVLDEMGRFYDWTEEEKATYRADVEAALANNDLAELK N - The surface accessible regions in the GlpO sequence are bolded above. This is also illustrated in
FIG. 28B , where the top row shows darker shaded cytoplasmic regions, the middle row shows darker shaded surface accessible regions and the bottom row shows darker shaded transmembrane regions. - The immunogenic antigen may be from 80 to 99% identical to the sequence of GlpO provided herein, wherein the antigen is able to generate protective antibodies against a streptococcus, such as, for example, Streptococcus pnuemoniae. In one embodiment, the GlpO immunogenic antigen has at least 70% identity, preferably 80 or 85%, such as at least 90% identity or at least 95, 98 or 99% identity to the GlpO sequence provided herein.
- The immunogenic composition can have PncO as the only antigen, PncO and GlpO as the only antigens or it can have additional antigens. For example, the immunogenic composition can comprise PncO and other Streptococcus antigens, such as antigens from S. pnuemoniae, particularly those that are at least partially or fully surface exposed. For example, the compositions can have stkP and PspA.
- The composition can comprise PncO and GlpO, and/or antigenic fragments thereof, which fragments are able to generate protective antibodies against a streptococcus, such as, for example, Streptococcus pnuemoniae. The antigenic fragments may be isolated fragments. The antigenic fragments are typically 15 to 30 amino acid (and all amino acid numbers therebetween) long and will ideally comprise an epitope from the surface exposed portions of the sequences. For example, the fragments may comprise amino acid sequences that contain the sequences of the surface exposed portions shown in
FIG. 28 for PncO and GlpO. - The formulation can include a carrier or excipient. The formulations can include an adjuvant to enhance the extent or nature of the immune reaction. Determination of the amount of the immunogenic antigen and/or the adjuvant can be in accordance with standard techniques in the pharmaceutical or veterinary arts.
- Adjuvants that may be usefully employed in the preparation of vaccines include the following: oil adjuvants, for example, Freund's complete and incomplete adjuvants, mineral salts, alum, silica, kaolin, and carbon, polynucleotides and certain natural substances of microbial origin. An example of an adjuvant is a non-covalent complex of alpha-lactalbumin and fatty acid. Fatty acids useful for making the complex include unsaturated cis C14 to C20 fatty acids. (See WO 2014/008465). An example of an adjuvant is monophsophryl A.
- With administration of immunogenic antigens, typically an adjuvant is used. For example, an adjuvant can be used as a 0.001 to 50 wt % solution in phosphate buffered saline, and the antigen is present in the order of micrograms to milligrams, such as about 0.0001 to about 5 wt %, such as about 0.0001 to about 1 wt %, such as about 0.0001 to about 0.05 wt %. The antigen can be present in an amount in the order of micrograms to milligrams, or, about 0.001 to about 20 wt %, such as about 0.01 to about 10 wt %, or about 0.05 to about 5 wt %.
- The present disclosure provides pharmaceutical preparations which comprise, consist essentially of, or consist of PncO or immunogenic fragments thereof. The preparations can comprise other antigens such as, for example, GlpO. In one embodiment, the only antigens in the preparation are PncO and GlpO and/or immunogenic fragments thereof. For example, the composition may comprise PncO and/or GlpO as the only polypeptides in the composition.
- The pharmaceutical preparations can comprise additives, such as diluent, adjuvant, excipient, or carrier. Such additives can be liquids, such as water and oils, saline, glucose or the like, and auxiliary, stabilizing, thickening, or lubricating agents, wetting or emulsifying agents, or pH buffering agents, gelling or viscosity enhancing additives, detergents and solubilizing agents (e.g.,
TWEEN® 20,TWEEN® 80 also referred to aspolysorbate 20 or 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol), bulking substances (e.g., lactose, mannitol), flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. See “Remington's Pharmaceutical Science”, 17th edition, 1985. Non-aqueous solvents or vehicles can be used such as propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved or resuspended just before use. The formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. - The present compositions can be provided as liquid preparations, suspensions, emulsions, tablets, pills, sustained-release formulations, emulsions, aerosols, sprays, or any other form suitable for introducing the compositions into a subject to generate an immune response protective against S. pneumoniae or other streptococcaciae. The compositions may be administered to a human or a non-human animal.
- The antigenic compositions can be administered in delivery vehicles, which can include, but are not limited to, nanoparticles, nanovesicles (such as liposomes or other lipidic structures) and biological or hybrid delivery vehicles. Liposomes may comprise one or more types of phospholipids known in the art. Nanovesicles comprising porphyrin conjugates can be used. The nanovesicles comprising porphyrin conjugates may have cobalt chelated to the porphyrin moiety. For example, the nanovesicles can comprise porphyrin phospholipid conjugate, phospholipid that is not conjugated to phospholipid, optionally cholesterol, and optionally PEG-phospholipid. The phospholipids can be any phospholipids, saturated or unsaturated, such as DOPC, DMPC and DSPC. Nanovesicle carrier capable of surface-orienting peptide-based antigens are useful for enhanced immune responses. The nanovesicles may have an in-built adjuvant component. A biological based delivery vehicle can also be used. For example, a hybrid vector delivery vehicle described in WO2016019126 can be used. The hybrid vehicle can have incorporated therein an adjuvant.
- The adjuvant can be administered as a separate component in the immunogenic compositions or it can be incorporated into the delivery vehicle.
- The antigenic compositions may be used with a hybrid vector delivery vehicle. For example, a hybrid vector designed to assist the intracellular delivery of antigen cargo to antigen presenting cells can be used. The hybrid vector can be a biological based vector. For example, as a combination of biomaterial and biological components, each chosen due to individual use as delivery vehicles, the combined vector allows synergistic delivery mechanisms and disparate engineering tools to influence the process of antigen transport. Thus, steps associated with antigen presenting cells (APC) targeting, uptake, activation, and intracellular antigen release have been designed through a combination of the two components of the hybrid device. Highlighting the dual engineering capabilities of the hybrid vector are the polymer chemistry steps used to conjugate a mannose ligand to the poly(beta-amino ester) shell of the device which aids in APC targeting and vector uptake. Similarly, expression and localization of the LyE protein to the bacterial component of the hybrid vector safely extends the dose limits of the device.
- A different aspect of the vector is also highlighted. Namely, the option for in situ antigen generation. Here, the biological core of the vector allows the molecular biology tools associated with a facile microbe like E. coli to be used in both antigen consolidation and internal expression prior to delivery. This capability makes the normal requirement of separate bioprocesses dedicated to antigen generation and purification unnecessary and allows a “one-pot” production and delivery device for vaccine applications.
- The hybrid vector design also offers options associated with stable storage and widespread distribution; however, features related to production and access are targets of future research. In the present work, the results illustrate the first directed application of the vector, tested in the context of pneumococcal disease. The hybrid vector demonstrated improved immune response metrics using a model protein antigen (PspA) when compared to traditional vaccine formulations with alum and CFA. More importantly, once the molecular biology tools of the vector were utilized to consolidate newly-identified antigens, protection was provided across a range of clinically-relevant S. pneumoniae strains and disease models.
- The antigens selected for consolidation to the hybrid vector are based upon those upregulated during virulent transition, thus, the objective is to target the disease-causing subset from a greater population of colonizing and asymptomatic S. pneumoniae cells. This capability was observed across different pneumococci strains, administration routes, and in vivo conditions, including disease onset triggered by influenza. Furthermore, the effectiveness of the antigens delivered with the hybrid vector resulted in protection extended to 10 additional S. pneumoniae strains. Though not all levels of protection were the same, complete protection was observed in 11 of 15 cases, emphasizing the broad coverage potential of the consolidated antigens tested in this study. Owing to the tools associated with the hybrid vector, even broader coverage can be expected upon the consolidation of additional virulence-associated antigens into the vector design. This feature, coupled with the conserved nature of the antigens identified and tested (Table 1 and
FIG. 21 ), offers an excellent prospect of combatting antigenic drift and the resulting reduction in vaccine efficacy. Such concerns currently plague various vaccines associated with this and other diseases. Thus, the conserved nature of the antigens selected and consolidation options provided through the hybrid vector offer a solution to this issue. - Balancing the capabilities offered by the hybrid design is the potential for toxicity given the bacterial nature of the vector's core and the cationic charge of the polymer coating. As demonstrated, the final vector provides attenuation through cellular engineering of the bacterial core and via the process of polymer coating. More importantly, the vector has not provoked any toxicity upon administration unless heightened dosages are utilized. Yet, even under enhanced dosage levels, it is possible to negate toxic effects due to the biological attenuation afforded by the LyE gene, providing another level of engineering design in applying the hybrid vector.
- Consolidating virulent-specific antigens to the hybrid device also offers a smart vaccine with in-built antigen production or an in situ means of cargo generation. Combined, the vector offers engineering elements that range from process-level scalability and distribution to cellular-level immune response tunability with the potential to be directed at a number of challenging vaccine opportunities beyond pneumococcal disease.
- The compositions can be administered to a population in general, or can be targeted to individuals who are at risk for developing Streptococcus infections such as S. pneumoniae. For example, it can be administered to any individual who is in close contact with an infected individual.
- The compositions can be introduced into a subject using any suitable administration route, including but not limited to parenteral, subcutaneous, intraperitoneal, intramuscular, intravenous, mucosal, topical, intradermal, and oral administration.
- Immunization can be done by way of a single dose or it can be done by multiple doses that are spaced apart. For example, an initial administration and subsequent booster doses can be used. The compositions can be administered alone, or can be co-administered or sequentially administered with other prophylactic (such as, for example, other immunogenic compositions) or therapeutic compositions (such as, for example, antibiotics).
- In one aspect, this disclosure provides a method of preventing pneumonia in an individual comprising administering to the individual an effective amount of a composition described herein. This disclosure also provides a method of reducing the overall incidence of pneumonia in a population comprising administering to a plurality of individuals in the population an effective amount of compositions described herein, whereby administration of the immunogenic compositions prevents the occurrence of pneumonia in at least some of the individuals in the population such that overall incidence of pneumonia n the population is reduced.
- The method of the present disclosure provides a strategy to induce an antibody-mediated immune response against a disease-causing subset of a commensal microbial population. Specifically, antigens associated with biofilm-released, virulent pneumococci have demonstrated unequivocal challenge protection and reduction in bacterial burden of a range of clinically-relevant S. pneumoniae strains under varying disease conditions. The results offer a response to a globally-relevant disease and growing concerns associated with current treatment options including risks posed by emerging serotype- and niche-replacement pathogens. Importantly, the same tools enabling the results of this work can be applied to continually identify and simultaneously deliver new antigens as a means to address the diversity and antigenic drift potential of S. pneumoniae and other pathogens that exhibit similar virulence progression.
- In one aspect, the present disclosure provides a method of identifying immunogens, such as genes, RNA, proteins, immunogens, or polypeptides that can be used for vaccine compositions against pathogens colonizing the nasal cavity mucosa—generally as a biofilm. Such pathogens will include new serotypes of S. pneumoniae, other bacteria (including those commonly found in the nasopharynx and those that colonize in addition), or other microbial targets (including viruses or fungal organisms). The method comprises inducing release of the pathogens by applying external triggers, including viral induced release or heat triggered release etc. For example, heat triggered release can be achieved by exposure to temperatures higher than normal body temperatures. For example, the biofilm release can be achieved by exposure to temperatures from 37° C. to 39° C. for about 1 to 6 hours, or more. The released cells can be collected and characterized. Specific serotypes can be identified, cultured and surface exposed proteins can be identified that are unique to the serotype, for example. The same analysis can identify numerous molecular antigenic targets, as introduced above that could also be valuable vaccine ingredients. The newly identified proteins or portions thereof can be used to determine if immunizations with these proteins or portions thereof (such as surface exposed portions) can induce immunity against a broad spectrum of S. pneumoniae and/or other microbial targets.
- The current work presents a strategy capable of providing directed protection against virulent, biofilm-released S. pneumoniae. Thus, the present strategy is based upon selectively targeting those pneumococci that are triggered for virulent biofilm escape in response to changes in the nasopharyngeal environment (
FIG. 1C ). - Through the combination of an in vitro biofilm model (
FIG. 2A ), which was treated with or without factors associated with virus-induced inflammation of the nasopharynx, and transcriptional analysis of the bacterial populations comprising this model, antigens were identified that were specifically upregulated in biofilm-released pneumococci which demonstrated increased virulence. S. pneumoniae is a human pathogen that, with the exception of a few strains, cannot cause invasive disease in mice. The biofilm model was used to condition a clinical isolate of S. pneumoniae (EF3030, serotype 19F), that is cleared from the bloodstream of mice when grown in broth, to become lethally infectious. Specifically, EF3030 cells released from biofilms by increased temperature (38.5° C., mimicking fever) induced septicemia and death in mice and thus offered a clinically-relevant surrogate model of human pneumococcal disease (FIGS. 2B-D ). Planktonic, broth grown EF3030 pneumococci or those mechanically isolated from biofilms had no such virulence. Initial protection was then investigated by immunizing with a range of promising new antigen targets (Table 1) selected on the basis of 1) conserved sequence homology across all S. pneumoniae strains (thus, offering broad coverage potential) and, critically, 2) specific prominence in the virulent, biofilm-released bacterial population compared with the asymptomatic biofilm population. Namely, antigen targets up-regulated in biofilm-released pneumococci were prepared as recombinant proteins and tested for protection relative to the established S. pneumoniae surface protein antigen (PspA), which is also up-regulated during virulence transition (FIG. 2E ). To better compare efficacy of novel antigens with PspA, a bacterial challenge dosage was chosen that resulted in incomplete protection with PspA vaccination. Under these conditions, GlpO (an α-glycerophosphate oxidase) and PncO (a bacteriocin ABC transporter transmembrane protein) demonstrated promising individual protection. However, complete protection and effective bacterial reduction were conferred upon immunization with both antigens (FIGS. 2F &G), an important result considering the effectiveness of the antigens against a clinical isolate of S. pneumoniae and a clear improvement relative to current vaccine candidates (i.e., PspA). -
TABLE 1 Antigen cloning summary Antigen Restriction Gene Primers Source Sites Plasmid Name dexB F: TAAGCACATATGCAAGAAAAATGGT D39 NdeI/XhoI pET21c pCJ05 GGCATAATGCCGTAG (SEQ ID NO: 3) R: TAAGCACTCGAGTTCCACACAGAAA GCATCCCA (SEQ ID NO: 4) htrA F: D39 NcoI/XhoI pET20b pCJ06 TAAGCACCATGGGGAAACATCTAAA AACATTTTACAA (SEQ ID NO: 5) R: TAAGCACTCGAGAGATTCTAAATCAC CTGAAC (SEQ ID NO: 6) glpO F: D39 SacI/XhoI pET21c pCJ07 TAAGCAGAGCTCGAATTTTCAAAAA AAACACGTGAATTGTC (SEQ ID NO: 7) R: TAAGCACTCGAGATTTTTTAATTCTG CTAAATCGTTGTTAG (SEQ ID NO: 8) stkP F: D39 NdeI/NotI pET21c pCJ08 TAAGCACATATGATCCAAATCGGCA AGATTTT (SEQ ID NO: 9) R: TAAGCAGCGGCCGCAGGAGTAGCTG AAGTTGTTTTA (SEQ ID NO: 10) blpB F: D39 NcoI/XhoI pET20b pCJ09 TAAGCACCATGGGGAATCCTAATCTT TTTAGAAG (SEQ ID NO: 11) R: TAAGCACTCGAGATCAGAATGGGTT AAAATTTTA (SEQ ID NO: 12) pncO F: EF3030 NdeI/XhoI pET21c pCJ10 TAAGCACATATGAAAAAGTATCAAC TTCTATT (SEQ ID NO: 13) R: TAAGCACTCGAGCCCCAAGACCCTAT GTAGAAAA (SEQ ID NO: 14) prtA F: D39 SacI/XhoI pET21c pCJ12 TAAGCAGAGCTCAAAAAAAGCACAG TATTGTC (SEQ ID NO: 15) R: TAAGCACTCGAGATCTTGATTTTTTTT CTTCAAT (SEQ ID NO: 16) - The delivery of GlpO and PncO, both recombinantly produced with 6×histitine tags, was facilitated using a novel cobalt porphyrin-phospholipid (Co-PoP) liposomal carrier capable of surface-orienting peptide-based antigens for enhanced immune responses and featuring an in-built adjuvant component (monophosphoryl lipid A) that outperformed comparative formulations featuring traditional alum and complete Freund's adjuvant (
FIGS. 5-7 ). The liposomal device thus offers a unique vaccine formulation based upon a simple and stable antigen-carrier complex without the need for advanced chemical conjugation. Furthermore, the technology is well-aligned with the antigen discovery and production techniques offered by the aforementioned biofilm model and well-established recombinant protein production. Therefore, we adopted the technology here in the delivery and assessment of GlpO and PncO. Looking forward, the Co-PoP delivery platform offers even more potential in the way of unprecedented valency of antigens discovered (i.e., the surface localization and presentation of 100s of additional protein or peptide antigens) and emphasizes the point here that even if relevant antigens are identified, their ultimate potency may not be realized unless effective delivery methods are employed. - The directed nature of the new antigens was then tested in a series of experiments presented in
FIG. 3A . Across different anatomical locations representative of bacterial colonization (nasopharynx) and displacement (nasopharynx lavage), disseminating pneumonia (lung), and invasive septicemia (blood), vaccinated and non-vaccinated mice were challenged with less virulent (planktonic) and virulent (biofilm-released) S. pneumoniae and bacterial clearance monitored over time. In the absence of an external stimulus (e.g., viral infection), mice will remain colonized with planktonic D39 or EF3030 for 1 to 3 weeks without infection of the lower respiratory tract or the development of bacteremia. However, biofilm-released bacteria will demonstrate a similar colonization pattern as compared to avirulent bacteria but will also have the propensity to disseminate into secondary anatomical sites and cause disease. Thus, in this study the planktonic EF3030 and D39 cells provided a clearance baseline to compare reduced bacterial loads using virulent challenge. Clearance of biofilm-released bacteria was only mediated in vaccinated mice; whereas, the bacterial load was significantly increased and lethal in non-vaccinated mice (FIG. 3A ). Interestingly, the rate of clearance of planktonic bacteria was unchanged despite vaccination. Thus, the data further support a directed vaccination strategy using GlpO and PncO. - However, the antigenic drift potential of S. pneumoniae emphasizes the need for any new antigens to be general and effective across a wide range of challenge strains (Table 2). To this end, the new antigens were tested in mice infected with a range of S. pneumoniae strains chosen for their notable difficulty to protect against and the variability between strains with regard to serotype and genetic background. Complete protection was provided for both sepsis and pneumonia challenge models (
FIGS. 3B &C;FIGS. 8&9 ). Ten additional strains were tested in protection experiments with average time to death ranging from 12-21 days as opposed to <3 days for controls (FIG. 10 ). These challenge assays included strains ofserotype -
TABLE 2 S pneumoniae strains used in the current study. Italicized strains are not currently included in commercial vaccines. Capsule Included in This Study Type Virulence Current Protection Strain (Serotype) Pattern Vaccines % D39 2 1 Yes 100% D39-Heat Released 2 4 Yes 100 % DBL2 2 2 Yes 100% A66.1 3 1 Yes 100 % WU2 3 1 Yes 100 % ATCC6303 3 2 Yes 100 % 3JYP2670 3 2 Yes 50 % TIGR4 4 2 Yes 100 % DBL5 5 2 Yes 66% WCH16-Heat Released 6A 4 Yes 50 % DBL6A 6B 2 Yes 66% ATCC-6312-Heat Released 12F 4 No 84% ATCC-10354-Heat Released 15B 4 No 100 % EF3030 19F 3 Yes 100% EF3030-Heat Released 19F 4 Yes 100% ATCC-6324-Heat Released 24 4 No 100% ATCC-6327-Heat Released 27 4 No 100% Virulence Pattern Lung Classification Carriage Infection Sepsis Comments 1 − ++ +++ Bacteria carries poorly and transitions to the blood wherever placed 2 ± ++ ++ Bacteria causes strong infection wherever placed; occasionally will transition to the blood and cause death 3 ++ +++ ± Bacteria carries well and infects locally but unlikely to kill; rarely transitions to the blood and causes death 4 ++ +++ ++ Bacteria carries well and causes strong infection wherever placed and can transition to the blood -
TABLE 3 PncO and GlpO antigen description and analysis. Strain Conservation Virulent Gene (% Homology) Expression (1og2) Average Surface Surface Size Relative to log2 Fold Surface Full Accessible Accessible Gene (bp) Function Planktonic Biofilm Change Accessible Protein Regions Epitopes pncO 690 Bacteriocin 8.5 4.8 6.6 Yes 95% 93% 97% ABC transporter transmembrane protein glpO 1,827 α- 9 5.9 7.4 Yes 99% 98% 98% glycerophosphate oxidase - In a final set of experiments presented in
FIG. 4 , we explored protection in an in vivo model that mimics the clinical progression of pneumococcal disease onset. Epidemiological evidence suggests that pneumococcal disease is strongly associated with a concomitant infection with upper respiratory tract viruses, such as influenza A virus (IAV). Mice were infected intranasally with IAV 48 hours after colonization with S. pneumoniae, a protocol designed to mediate the release of virulent pneumococci from colonizing biofilms for subsequent dissemination to the lungs and blood (FIG. 4A ). Mice vaccinated with GlpO and PncO displayed a limited spread of D39 and EF3030 S. pneumoniae strains in this clinically-relevant model system with the reduced onset of dissemination of virulent organisms indicated onday 1 post viral infection and significantly pronounced reduction in the lung and the blood on day 5 (FIGS. 4A &B). Of major importance is the fact that the nasopharyngeal burden in immunized and non-immunized animals remained unchanged, suggesting that the harmless and potentially beneficial commensal colonization was unaffected. This further supports a paradigm shift in protection against “accidental pathogens” or those commensals that colonize asymptomatically but have the capacity to cause disease in response to inflammation or other external triggers. When using this same in vivo model of IAV-induced pneumococcal disease, full protection against septicemia and death was conferred by the combination of GlpO and PncO using traditional immunization while partial protection was accomplished via adoptive/passive vaccination strategies (FIGS. 4E &F). The latter result indicates an important role of the humoral immune system arm in the mechanism driving the results obtained throughout this study, while simultaneously suggesting that an additional T cell response is also contributing. - This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the University at Buffalo, Buffalo, N.Y. All bacterial inoculations and treatments were performed under conditions designed to minimize any potential suffering of the animals.
- Bacterial and cell culture media and reagents were purchased from Fisher Chemical and Sigma-Aldrich (St. Louis, Mo.). Chemically defined bacterial growth medium (CDM) was obtained from JRH Biosciences, Lexera, Kans. Sheep blood was purchased from Hemostat Laboratories (Dixon, Calif.). All remaining reagents were purchased from Sigma-Aldrich.
- All antigen genes were cloned from the genomic DNA of S. pneumoniae strains using primers summarized in Table 1. Each PCR product was then inserted into pET expression vectors as outlined in Table 1 using the flanking restriction sites indicated (designed within the primers). Constructs were verified by colony PCR and restriction digest analysis and were then chemically transformed into BL21(DE3) with resulting single-colony transformants cultured in 3 mL lysogeny broth (LB) at 37° C. with shaking prior to 15% glycerol stock storage at −80° C. Expression was initially confirmed by 3-5 mL LB cultures started from glycerol stocks and cultured at 37° C. with shaking until an OD600 of 0.4 was achieved. After which, cultures were induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) (1 mM) for 1 hour. Upon collection via centrifugation, cells were washed twice with PBS and resuspended in 25 mM Tris-HCL prior to boiling with loading dye and expression analysis/confirmation via SDS-PAGE.
- Glycerol stocks were then used to start overnight 3 mL LB cultures incubated at 37° C. with shaking and used to inoculate (1% v/v) 1 L of terrific broth, which was then grown to a concentration of 0.4-0.6 OD600 under the same culture conditions. IPTG induction (100 μM) occurred at this point prior to continued culture overnight at 22° C. After clarification by centrifugation, cells were resuspended in Buffer A (50 mM Na2PO4, 500 mM NaCl, and 10% glycerol) and lysed via French press. The resulting lysate was clarified by centrifugation and the resulting lysate supernatant clarified further via ultracentrifugation at 142,000×g (RFC) for 45 minutes. Lysate collected was confirmed by SDS-PAGE at this stage prior to column purification.
- Antigen protein products were then purified by passing lysate supernatant through a fast protein liquid chromatography column (GE Healthcare HisTrap HP, 1×1 mL) using 2% Buffer B (50 mM Na2PO4, 500 mM NaCl, 10% glycerol, and 250 mM imidazole) and 98% Buffer A as the mobile phase. The protein was eluted with 100% Buffer B, and a UV absorbance of 280 nm was used to detect the fractions containing protein in the elution. Those fractions were pooled and protein content characterized by SDS-PAGE and quantified by Pierce™ Micro BCA™ Protein Assay assessment.
- Antigen cobalt porphyrin-phospholipid (Co-PoP) liposomal carrier vectors were generated as described previously (Shao et al.,
Nat Chem 7, 438-446, (2015)). Each injection dose contained 25 μg monophosphoryl lipid A (MPLA) in liposomes comprising DOPC:cholesterol:MPLA:Co-PoP at a molar ratio of 50:30:5:5. After dissolving liposomes in chloroform in a test tube, the solvent was evaporated and the film was further dried under vacuum overnight. Liposomes were then rehydrated with phosphate buffered saline (PBS) and sonicated. Binding ability of new antigens was evaluated by incubating 25 μg of protein with 20 μg of liposomes in 200 μL PBS within a well of a 96-well plate. Fluorescence in the FRET channel (ex: 430 nm, em: 525 nm) was measured periodically with a fluorescence microplate reader (Tecan Infinite II). Data were normalized to the FRET signal for protein without addition of liposomes. Dynamic light scattering was used to evaluate the particle diameter and zeta potential of liposomes containing three concentrations of PspA (0, 5, and 15 μg). Once binding was confirmed, antigen was incubated at 4° C. with Co-PoP liposomes overnight before animal injection.FIGS. 5-7 summarize liposomal carrier characterization and immunization optimization with model antigen PspA. - Outbred 6-week-old female CD-1 mice (Harlan Laboratories, Indianapolis, Ind.) were used in immunization experiments. Mice were immunized by intraperitoneal injection (i.p.; 200 μL), subcutaneous injection (s.q.; 200 μL), and intranasal aspiration (40 μL). Final antigen (Table 1) doses ranged from 5 to 15 μg in either naked or liposomal format. When combined, PncO and GlpO (Table 3) were administered at 15 μg each. After 14 days, mice were boosted with the same formulations. At
day 14 andday 28, serum samples were collected from the mice by retro-orbital bleeding. For passive immunizations, respective sera were diluted ten times and administered via i.p. injection (200 μL). - Bacterial strains used in this study are listed in Table 2 and were initially grown on Todd-Hewitt agar plates supplemented with 0.5% yeast extract and 5% sheep blood and incubated overnight at 37° C. Single colonies were used to inoculate 5 mL Todd-Hewitt broth containing 0.5% yeast extract and incubated at 37° C. to an OD600 of 0.6. At this point, bacteria were used for challenge studies after washing one time with and resuspending in PBS.
- NCI-H292 epithelial cells were cultured in RPMI-1640 medium in T75 flasks at 37° C. and 5% CO2. After reaching 100% confluency, H292 cells were prefixed in 4% buffered paraformaldehyde at 34° C. for 48 hours followed by three washes with PBS. CDM-grown pneumococci were then seeded onto fixed H292 cells with change of media occurring every 12 hours. Formed biofilms were exposed to heat (38.5° C.) for 4 hours and released cells were then collected by centrifugation, washed and resuspended in PBS, and quantified by OD600 measurement. Biofilm associated cells were disrupted by gentle pipetting, collected by centrifugation, washed and resuspended in PBS, and quantified by OD600 measurement.
- Biofilms grown in vitro for 48 hours were fixed using 2.5% glutaraldehyde, 0.075% ruthenium red, and 0.075 M lysine acetate in 0.1 M sodium cacodylate buffer (pH 7.2) for 1 h at 22° C. This procedure has been shown to retain carbohydrate structures and improve preservation of biofilm morphology. Samples were washed three times without shaking for 15 min at 22° C. in 0.075% ruthenium red in 0.2 M sodium cacodylate buffer and were then dehydrated with a graded series of ethanol solutions (10, 30, 50, 75, 95, and 100%) at 22° C., with 15 min used for each step. Samples were exchanged into 100% hexamethyldisilazane and allowed to air dry before being mounted onto stubs, carbon coated, and analyzed using an SU70 scanning electron microscope at an acceleration voltage of 5.0 kV (available through the South Campus Instrumentation Center, University at Buffalo, Buffalo, N.Y.).
- To induce sepsis or pneumonia, mice were administered i.p. or i.n. (with isoflurane), respectively, with 1×104 to 1×106 CFU of pneumococci strains (Table 2). To induce colonization, mice were administered 1×106 CFU bacteria i.n. without isoflurane. To mimic influenza-induced pneumonia, pneumococci colonization was followed by intranasal inoculation with 40 plaque forming units of IAV. IAV strain A/PR8/34 (H3N2) (ATCC VR-777) was used, and titers were determined by plaque assays. Mice were monitored every four hours for signs of morbidity (huddling, ruffled fur, lethargy, and abdominal surface temperature). Mice found to be moribund were euthanized via CO2 asphyxiation and cervical dislocation.
- At predefined time points (24 and 48 h post-infection for intraperitoneal and intranasal challenges, respectively) or upon becoming moribund, mice were euthanized (as described above) and a combination of nasopharynx tissue, nasopharyngeal lavage fluid, lung, liver, spleen, and blood samples was collected and bacterial burden determined as described. Briefly, tissue and organ homogenate, lavage fluid, and blood were sonicated to ensure dissociation of bacterial aggregates and then serially diluted on tryptic soy and 5% blood agar plates prior to enumeration. Tissue burden data and associated challenge data are presented in
FIGS. 8 and 9 . - To characterize antibody titers associated with delivery optimization (
FIG. 6 ), an enzyme-linked immunosorbent assay (ELISA) was performed by coating a 96-well Costar high binding polystyrene plate with 10 μg/mL PspA in tris-buffered saline (TBS) at 4° C. overnight. The plate was blocked with 3% BSA in TBS-Tween 20 (TBS-T) for one hour at 22° C. Sera was diluted into TBS-T in ratios of 1:1,000, 1:5,000, 1:7,500 and 1:10,000 and added to the plate. The plates were then incubated at 37° C. with mild agitation for three hours. The secondary antibody (Anti-Mouse IgG, IgA, IgM (H+L) Highly X-Adsorbed-Biotin) was added to the wells in a 1:1,000 ratio and agitated for two hours. Streptavidin was added to each well in a 1:1,000 ratio and allowed to shake for 30 minutes. The signal was developed with p-nitrophenyl phosphate and the reaction was quenched using 0.75 M NaOH. The signal was detected using a plate reader spectrophotometer at an absorbance of 405 nm. - The data presented in
FIGS. 1D , F, and G were obtained from the CDC's Active Bacterial Core Surveillance (ABC) for Streptococcus pneumoniae (cdc.gov/abcs/reports-findings/surv-reports.html). The infection rate for infectious pneumococcal disease was obtained from the annual reports from 1998-2014 for both children under 5 and the total population. The data presented inFIG. 1E was obtained from Table 2 in Richter, et al (2013), which provided information regarding pneumococcal strain prevalence from 1998-2011; the strain distribution for children under 5 was organized into three different groups (PCV-7, PCV-13, and NVT strains).FIG. 1F represents the efficacy of the PCV-7 vaccine by plotting the percent reduction in infection rate following the introduction of the vaccine. The baseline infection rate was determined by averaging the rates from 1998-1999. Similarly, the efficacy of the PCV-13 vaccine (FIG. 1G ) was demonstrated by plotting the percent reduction in infection rate using the 2008-2009 infection rates as a baseline. The dashed lines inFIGS. 1F and 1G correspond to the prevalence of the PCV-7 and PCV-13 strains, respectively one year prior to the introduction of the vaccines. - Column comparisons were analyzed for statistical significance using a two-tailed Student t test for unpaired data. Multivariance analysis was done using one-way analysis of variance (ANOVA) that was corrected using the Bartlett variance test and for multiple comparisons using the Bonferroni multiple-comparison test. For both tests, a P value of 0.05 was considered significant. Statistical analysis was performed using the GraphPad Prism software (version 6.0h.283; GraphPad Software Inc., La Jolla, Calif.). All data resulted from a minimum of three samples with animal experiments using a minimum of four (and in most cases twelve) subjects.
- In this example, new antigens associated with pneumococcal disease virulence were utilized as a basis for testing the delivery and adjuvant capabilities of a hybrid biological-biomaterial vector. The hybrid design provides 1) dual passive and active targeting of antigen presenting cells (APCs), 2) natural and multi-component adjuvant properties, 3) dual intracellular delivery mechanisms, and 4) a simple formulation mechanism. In addition, the hybrid device enables device-specific, or in situ, antigen production via the biological component of the vector. This capability eliminates the need for dedicated antigen production and purification prior to vaccination efforts while leveraging the features of the overall delivery device. Here, we present the potent utilization of the vector towards pneumococcal disease highlighted by protective capabilities when tested against a range of clinically-relevant Streptococcus pneumoniae strains. More broadly, the results here point to similar levels of success with other diseases that would benefit from the production, delivery, and efficacy capabilities offered by the hybrid vector.
- This work features a hybrid antigen delivery vector composed of biological and biomaterial components each designed to facilitate, enhance, and direct the immune response process. The biological portion of the vector is a bacterial cell (nonpathogenic Escherichia coli) that, as a result of the microbial framework, possesses natural adjuvant properties and also allows the delivery of either protein or genetic antigens. Coating of the bacterial core with a poly(beta-amino ester) (PBAE) covalently linked to mannose provides a combined delivery device with properties to assist antigen cargo cellular translocation. Namely, the size of the overall vector allows passive targeting of phagocytic APCs programmed to engulf such particles; in addition, the vector's composition and the surface characteristics endowed by the mannosylated PBAE will engage APC receptors and enhance uptake upon vector administration. The biomaterial and biological components can also be designed to facilitate endosomal escape and cytosolic trafficking post-phagocytosis. Finally, the bacterial core of the vector allows antigen cargo to be delivered as protein, nucleic acid, or both.
- This last feature also provides an opportunity to directly generate and maintain the required antigen in lieu of a dedicated bioprocess to produce genetic or protein formats. Thus, the hybrid vector provides the added capability of “in situ” antigen production that can be coupled to the delivery features of the device. Combined, the vector offers a broad array of engineering opportunities meant to improve vaccine production (via rapid and scalable means of component generation, in situ antigen provision, and simple hybrid formulation) and potency (via the innate design and diverse engineering tools, i.e., polymer chemistry and molecular biology).
- This premise is the basis for the following results. Within the framework of pneumococcal disease, new antigens were generated and delivered via the hybrid vector. Directed, broad, and potent results were obtained as assessed within disease challenge assays against a range of clinically-relevant S. pneumoniae strains. Beyond the protection data collected for this particular disease type, the vector format offers opportunities for other maladies (such as cancer or viral-based infectious disease) similarly expected to require an advanced delivery device capable of supporting a similarly advanced immune response.
- Hybrid Vector Assessment with Model and Novel Antigen Delivery
- The data presented in this work marks the first application of the hybrid vector and the utility of the device is assessed in the context of pneumococcal disease, which afflicts millions worldwide annually especially resource-limited children and elderly. Initial experiments were dedicated to optimizing and characterizing the use of the hybrid vector when incorporating a model protein antigen for pneumococcal disease, PspA. The results demonstrate improved outcomes when compared to traditional vaccine formulations containing either alum or complete Freund's adjuvant (CFA;
FIGS. 11A &C and 14). Importantly, these results were consistent across three different administration routes (intraperitoneal [IP], subcutaneous [SQ], and intranasal [IN]). There was also a balanced antibody response (FIGS. 11B and 15 ) with a transition over time to enhanced IgG content for IP and SQ administrations and IgG and IgA content for IN administration. - Dosing levels of the hybrid vector containing PspA were also assessed and optimized across administration routes and in response to S. pneumoniae sepsis challenge using a D39 strain (
FIG. 16 ). D39 was selected because of its notable virulence profile and acceptance as one of the harshest preclinical challenge strains. Increasing the challenge inocula of S. pneumoniae can be countered with increasing hybrid vector vaccination dosages (FIG. 16A ); however, particularly aggressive challenge levels (106 S. pneumoniae cells) require a vaccination dose of ≥1010 hybrid devices to mediate full protection. Due to the bacterial content of the hybrid vector, it is important to assess such enhanced dosage levels for associated toxicity. Across administration routes, toxicity was not observed until ≥1013 hybrid vectors were administered (FIG. 16B ). The design of the hybrid vector, however, allows both the chemical and biological aspects of the device to extend dosing level safety. Namely, the vector's polymer coating and the inclusion of a lysis E (LyE) gene provide alternative mechanisms of attenuation. In the case of LyE, the membrane perforative activity of this protein affords safety of up to 1020 dose levels for the resulting hybrid device (FIG. 16B). Given the added tissue sensitivity associated with intranasal administration, histology was performed with 1013 hybrid devices. This administration dose was selected as a result of being the highest delivery load with no associated toxicity. In support of the mouse subject viability tests inFIG. 16B , no tissue damage was observed via histological analysis as compared to the untreated control (FIG. 17 ). - The hybrid vector was then used to screen several antigen candidates selected due to enhanced expression during S. pneumoniae virulence transition during the course of pneumococcal disease progression (Table 4). As such, the antigens would serve as the basis of a “smart vaccine” capable of directing a subsequent immune response to only a virulent sub-set of S. pneumoniae cells (
FIG. 12 ).FIG. 11D presents the degree of protection provided by antigen candidates StkP, DexB, GlpO, and PncO relative to PspA, with each individually delivered via the hybrid vector. Though individual protection varied by antigen, the design parameters of the hybrid vector allowed consolidated testing of all the candidates. Specifically, a two expression plasmid system (pCJ10 and pLF; Tables 1&5 andFIG. 18 ) was utilized to enable the vector-based in situ production of the antigen products while leveraging the delivery capabilities of the hybrid device. Using the two-plasmid system, complete protection was provided against the S. pneumoniae challenge strain D39 in both sepsis and pneumonia mouse models (FIGS. 11E &F). -
TABLE 4 DexB, GlpO, StkP, and PncO antigen description and analysis. Strain Conservation Virulent Gene (% Homology) Expression (log2) Average Surface Surface Size Relative to log2 Fold Surface Full Accessible Accessible Gene (bp) Function Planktonic Biofilm Change Accessible Protein Regions Epitopes dexB 1,608 Glucan 1,6-α-1.5 1.5 1.5 No 98% N/A N/A glucosidase glpO 1,827 α- glycerophosphate 9 5.9 7.4 Yes 99% 98% 98% oxidase stkP 1,980 Serine/threonine 0.7 0.7 0.7 Yes 99% 99% 99.4% protein kinase pncO 690 Bacteriocin ABC 8.5 4.8 6.6 Yes 95% 93% 97% transporter transmembrane protein -
TABLE 5 Consolidated plasmid (pLF) cloning summary Antigen Restriction Gene Primers Source Sites dexB F: pCJ05 BamHI/AscI GCGGGATCCCAAGAAAAAT GGTGGCATAATGCCGTAG (SEQ ID NO: 17) R: ATAGGCGCGCCTTATAGTA ATTCCACACAG (SEQ ID NO: 18) glpO F: pCJ07 SalI/NotI GCGGTCGACAAGGAGATAT AATGGAATTTTCAAAAAAA AC (SEQ ID NO: 19) R: GCGGCGGCCGCTTAATTTT TTAATTCTGC (SEQ ID NO: 20) stkP F: pCJ08 NdeI/MunI GCGCATATGATCCAAATCG GCAAGATTTTTG (SEQ ID NO: 21) R: GCGCAATTGTTAAGGAGTA GCTGAAGTTGTTT TAG (SEQ ID NO: 22) pspA F: pUAB055 FseI/XhoI ATAGGCCGGCCAAGGAGAT ATAATGGAAGAATCTCCCG TAGCCA (SEQ ID NO: 23) R: ATACTCGAGTTATTCTGGG GCTGGAGTTTCTGGA (SEQ ID NO: 24) - To demonstrate the potency and versatility of the hybrid vector two-plasmid system, challenge levels and strains of S. pneumoniae were varied within vaccine protection assays. Strain D39 challenge was tested up to 1010 cells (
FIG. 19 ) with strong protection (>80% survival) observed for the 107 inoculum and varying degrees of protection provided beyond this level across administration routs. Protection conferred at these advanced challenge levels is considered impressive and highlights the combined adjuvant, delivery, and antigen consolidation capabilities of the hybrid vector. Furthermore, as supported by the data ofFIG. 16 , even better levels of protection would be expected with increased doses of the hybrid vector, readily possible as a result of engineering the degree of vector attenuation. - Finally, to further assess the protective capabilities of the antigens delivered with the hybrid vector, vaccination was tested against an extended panel of S. pneumoniae strains representing diverse serotypes notably difficult to protect against with current vaccine formulations; complete protection and reduced bacterial burden were observed (
FIGS. 11G &H and 20). - The directed nature of the vaccination strategy was tested first by comparing vaccinated and non-vaccinated mice subjects with avirulent and virulent S. pneumoniae strains (
FIG. 13A ). In these experiments, S. pneumoniae strain EF3030 was used due to planktonic (or broth cultured) cells demonstrating an avirulent phenotype; whereas, those cells released from in vitro or in vivo biofilms are virulent and cause disease (FIG. 12 ). The avirulent strains are cleared either with or without vaccination; whereas, only vaccinated mice are capable of demonstrating virulent bacterial clearance over time. This effect is further tested in the context of S. pneumoniae colonization followed by the addition of an in vivo virulence trigger (administration of influenza A virus [IAV]). Designed to more closely mimic the common clinical setting where influenza spurs pneumonia development, results indicate that bacterial dissemination is significantly reduced over time, in line with the theme of the immune response targeting only virulent populations, while complete protection is maintained with the consolidated set of antigens tested (FIGS. 13B ,C,&D). - The consolidated aspect of the vaccine formulation also offers extended protection. Namely, the conserved nature of the individual antigens (Table 4), when presented in combination, provides the potential to cover a broad range of S. pneumoniae strains (Table 2). Extended protection was thus tested against a series of 10 additional S. pneumoniae strains with protection enhancement observed in all cases and complete protection provided in six cases (
FIG. 13E ). - Though data presented support the broad protection potential of the consolidated antigens generated and delivered within the hybrid vector, the mutational potential of individual and combined antigens was predicted to further assess wide-spread and extended utilization of the vaccination strategy (
FIG. 21 ). The results emphasize the cumulative resistance to mutation of the combined antigen vaccination strategy. Taken together, utilizing five antigens specific to virulence provides ample coverage and resistance to strain evasion. Thus, antigenic drift, as a result of innate S. pneumoniae mutation, and the associated threat to vaccine efficacy is minimized through consolidation. - Experimental Design. A hybrid biological-biomaterial vector was tested in the delivery of virulent-specific antigens targeting pneumococcal disease progression. Success was assessed by mouse model immune response outcomes that included balanced antibody profiles, a directed targeting of virulent S. pneumoniae cells, reduced bacterial dissemination and tissue burden, and challenge protection. The hybrid vector allowed innate (or in situ) maintenance, consolidation, and production of the antigens in addition to other features that span vaccine production and enhanced delivery capability.
- This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the University at Buffalo, Buffalo, N.Y. All bacterial inoculations and treatments were performed under conditions designed to minimize any potential suffering of the animals.
- Materials. Bacterial and cell culture media and reagents were purchased from Fisher Chemical and Sigma-Aldrich (St. Louis, Mo.). Chemically defined bacterial growth medium (CDM) was obtained from JRH Biosciences, Lexera, Kans. Sheep blood was purchased from Hemostat Laboratories (Dixon, Calif.). Monomers were purchased from Sigma-Aldrich (St. Louis, Mo.) and TCI (Portland, Oreg.). Acetone (HPLC), chloroform (HPLC), n-hexadecane (99%), DMF (HPLC), and DMSO (≥99.7%) were purchased from Fisher Chemical. Phosphate buffered saline (PBS) was purchased from Life Technologies (Grand Island, N.Y.). All remaining chemicals and reagents were purchased from Sigma-Aldrich.
- Polymer Synthesis. The polymer used in this study, D4A4-Man, was synthesized in a four-step reaction (
FIG. 22 ). Briefly, instep 1, allyl-α-D-mannopyranoside (ADM) was synthesized by dissolving 3 g of D-(+)-mannose and 18 mg p-TsCl in allyl alcohol (20 mL) at 90° C. under reflux for 24 h. The resulting reaction solution was concentrated by vacuum distillation at 35° C. Next, instep 2, acrylate-terminated D4A4 was synthesized in DMSO at a 1:1.2 amine/diacrylate molar ratio for 5 days at 60° C. with continuous stirring at 1,000 rpm. Acrylate-terminated polymers were purified by dialysis followed by evaporation under vacuum. Dialysis procedures were conducted against acetone using molecular porous membrane tubing (Spectra/Por Dialysis Membrane, Spectrum Laboratories Inc.) with an approximate molecular weight cut-off at 3,500 Da. Instep 3, acrylate-terminated D4A4 was reacted with excess ethylenediamine to amine-cap the terminal ends (D4A4-EDA). Specifically, acrylate-terminated D4A4 was dissolved in DMSO at 167 mg/mL and reacted with 5 M ethylenediamine (in DMSO) at room temperature for 24 h. D4A4-EDA was purified by dialysis followed by evaporation under vacuum. In the last step, D4A4-EDA was reacted with ADM at a 1:2 molar ratio in DMSO at 90° C. for 24 h and then purified via dialysis. Structure and purity of D4A4-Man were confirmed using 1H NMR spectroscopy. - Bacterial Strains and Plasmid Generation. Antigen genes were amplified from the genomic DNA of S. pneumoniae strains using primers summarized in Table S2. Each PCR product was cloned into pET expression plasmids using the flanking restriction sites indicated (designed within the primers). Constructs were verified by colony PCR and restriction digest analysis and were then chemically transformed into the BL21(DE3) E. coli cell line (Novagen). Resulting single-colony transformants were cultured in 3 mL lysogeny broth (LB) at 37° C. with shaking prior to 15% glycerol stock storage at −80° C. Plasmid selection antibiotics were used as needed during bacterial culture within LB medium. Expression was confirmed by 3-5 mL LB cultures started from glycerol stocks and grown at 37° C. with shaking until an OD600 of 0.4 was achieved. After which, cultures were induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) (1 mM) for 1 hour. Upon collection via centrifugation, cells were washed twice with PBS and resuspended in 25 mM Tris-HCL prior to boiling with loading dye and expression analysis/confirmation via SDS-PAGE. Plasmid pUAB055 was used to express and clone the pspA gene.
- To employ the two-plasmid system, pCJ10 was used in conjunction with a plasmid containing pspA, dexB, stkP, and glpO. The consolidated plasmid was assembled by sub-cloning each respective gene into a pACYCDuet-1 plasmid (
FIG. 18 and Table 5). To construct pLF, the restriction enzymes/sites were utilized for the corresponding multiple cloning sites (MCSs) within pACYCDuet-1. Plasmids were chemically transformed into E. coli strain BL21(DE3) (as the basis for hybrid device preparation) and resulting transformants prepared and stored as glycerol stocks. - Hybrid Device Preparation. Bacterial and hybrid vectors were prepared from bacterial cultures inoculated at 2% (vol/vol) from overnight starter cultures. Following incubation at 37° C. with shaking until 0.4-0.5 OD600, samples were induced with 0.1 mM IPTG at 30° C. for 3 h. Bacterial vectors were then washed once and standardized to 0.5 OD600 in PBS; whereas, bacteria to be used in hybrid vector formation were washed once and standardized to 1.0 OD600 in 25 mM NaOAc (pH 5.15). Polymer was dissolved in chloroform, desiccated, and resuspended at 1 mg/mL in 25 mM NaOAc (pH 5.15) before being added in an equal volume to bacteria and mixed by vortexing on setting 5 (Analog Vortex Mixer; Fisher Scientific) for 10 s. Polymer/bacteria self-assembly was allowed to continue for 15 min, and devices were then diluted in PBS.
- Hybrid Vaccine Immunization. Outbred 6-week-old female CD-1 mice (Harlan Laboratories, Indianapolis, Ind.) were used in immunization experiments. Mice were immunized by IP injection (200 μL), SQ injection (200 μL), and IN aspiration (40 μL) using isoflurane; unless indicated otherwise, 107 hybrid vectors were used in vaccination experiments. Immunization of controls included sham (PBS; all samples were prepared in PBS as the background solution); PspA plus alum; and PspA plus complete Freund's adjuvant (CFA), which was replaced with Incomplete Freund's Adjuvant (IFA) during booster immunizations. After 14 days, mice were boosted with the same formulations except in the case of the CFA adjuvant as noted above. At
days - S. pneumoniae Bacterial Preparation and Biofilm Release. S. pneumoniae strains used in this study are listed in Table 6 and were initially grown on Todd-Hewitt agar plates supplemented with 0.5% yeast extract and 5% sheep blood and incubated overnight at 37° C. Single colonies were used to inoculate 5 mL Todd-Hewitt broth containing 0.5% yeast extract and incubated at 37° C. to an OD600 of 0.6. At this point, S. pneumoniae strains used for challenge studies were washed one time with and resuspending in PBS. NCI-H292 epithelial cells were cultured in RPMI-1640 medium in T75 flasks at 37° C. and 5% CO2. After reaching 100% confluency, H292 cells were prefixed in 4% buffered paraformaldehyde at 34° C. for 48 hours followed by three washes with PBS. CDM-grown pneumococci were then seeded onto fixed H292 cells with change of media occurring every 12 hours. Formed biofilms were exposed to heat (38.5° C.) for 4 hours and released cells were then collected by centrifugation, washed and resuspended in PBS, and quantified by OD600 measurement. Strains presented in Table 6 are a mix of mouse-passaged strains, which directly confer virulence upon culture and administration, and clinical isolates, which usually do not cause disease upon direct administration and require heat release from the in vitro biofilm model (detailed directly above) to render a virulent phenotype.
- Challenge Models. To induce sepsis or pneumonia, mice were administered IP or IN (with isoflurane), respectively, with 1×104 to 1×1010 CFU of pneumococci strains (Table 6). To induce colonization, mice were administered 1×106 CFU bacteria IN without isoflurane. To mimic influenza-induced pneumonia, pneumococci colonization was followed by intranasal inoculation with 40 plaque forming units of IAV. A mouse-adapted IAV strain A/PR/8/34 (H1N1) (ATCC VR-95) was used, and titers were determined by plaque assays. Mice were monitored every four hours for signs of morbidity (huddling, ruffled fur, lethargy, and abdominal surface temperature). Mice found to be moribund were euthanized via CO2 asphyxiation and cervical dislocation.
- Tissue Bacterial Count. At predefined time points (24 and 48 h post-infection for IP and IN challenges, respectively) or upon becoming moribund, mice were euthanized (as described above) and a combination of nasopharynx tissue, nasopharyngeal lavage fluid, lung, liver, spleen, and blood samples was collected and bacterial burden determined. Briefly, tissue and organ homogenate, lavage fluid, and blood were homogenized to ensure dissociation of bacterial aggregates and then serially diluted on tryptic soy and 5% blood agar plates prior to enumeration.
- Histology Analysis. Following induction of isoflurane anesthesia, a midline abdominal incision was made and the abdominal aorta transected to exsanguinate and euthanize the animal. A midline incision was continued through the thoracic cavity and neck to allow injection of 5 mL normal saline into the right ventricle of the heart to flush the pulmonary vasculature of residual blood. A luer-
lock hubbed 20 ga×½″ cannula was inserted into the trachea and secured in place with a suture. The lungs were fixed by insulflation with 10% neutral buffered formalin at 20 cmH2O for 24 h at room temperature. The lung lobes were removed, embedded in paraffin, and 5 μm tissue slices were prepared and stained with hematoxylin and eosin by standard histopathology techniques. Histology images were acquired with an Aperio ScanScope CS slide scanner (Leica Biosystems, Buffalo Grove, Ill.) using a 40×objective lens and subsequently analyzed using Aperio ImageScope software (v.12.3 Leica Biosystems). - Antibody Analysis. To characterize antibody titers associated with delivery optimization, an enzyme-linked immunosorbent assay (ELISA) was performed by coating a 96-well Costar high binding polystyrene plate with 10 μg/mL PspA in tris-buffered saline (TBS) at 4° C. overnight. The plate was blocked with 3% BSA in TBS-Tween 20 (TBS-T) for one hour at 22° C. Sera was diluted into TBS-T in ratios of 1:1,000, 1:5,000, 1:7,500 and 1:10,000 and added to the plate. The plates were then incubated at 37° C. with mild agitation for three hours. The secondary antibody (Anti-Mouse IgG, IgA, IgM (H+L), IgE, Highly X-Adsorbed-Biotin) was added to the wells in a 1:1,000 ratio and agitated for two hours. Streptavidin was added to each well in a 1:1,000 ratio and allowed to shake for 30 minutes. The signal was developed with p-nitrophenyl phosphate and the reaction was quenched using 0.75 M NaOH. The signal was detected using a plate reader spectrophotometer at an absorbance of 405 nm.
- Statistical Analysis. Column comparisons were analyzed for statistical significance using a two-tailed Student t test for unpaired data. Multivariance analysis was done using one-way analysis of variance (ANOVA) that was corrected using the Bartlett variance test and for multiple comparisons using the Bonferroni multiple-comparison test. For both tests, a P value of 0.05 was considered significant. Statistical analysis was performed using the GraphPad Prism software (version 6.0h.283; GraphPad Software Inc., La Jolla, Calif.). All data resulted from animal experiments using six to twelve subjects per group except histology analysis, which utilized two mouse subjects per group.
- This example provides additional data describing PncO and GlpO utilized in an expanded sepsis model. Results are shown in
FIGS. 23-27 . In this example, adjuvant components were added to the GlpO and PncO protein antigens and testing was carried out as described in the above examples. Across the adjuvants tested with GlpO and PncO, there is generally a similar trend of vaccination effectiveness (measured as protection against disease challenge).
Claims (16)
1. A composition comprising an immunologically effective amount of an isolated PncO polypeptide having a sequence of SEQ ID NO:1, or having at least 90% homology to SEQ ID NO:1, in a pharmaceutical carrier.
2. The composition of claim 1 , where the only immunological component is PncO.
3. The composition of claim 1 , further comprising isolated GlpO having a sequence of SEQ ID NO:2, or having at least 90% homology to SEQ ID NO:2.
4. The composition of claim 1 , further comprising an adjuvant.
5. The composition of claim 1 , wherein the polypeptide is incorporated in a delivery vehicle.
6. The composition of claim 5 , wherein the delivery vehicle is a nanovesicle, nanoparticle, microvesicle, or hybrid delivery vehicle.
7. A nanovesicle having incorporated therein a PncO polypeptide having a sequence of SEQ ID NO:1 or having at least 90% homology to SEQ ID NO:1, and/or a GlpO polypeptide having a sequence of SEQ ID NO:2 or having at least 90% homology to SEQ ID NO:2.
8. The nanovesicles of claim 7 , wherein the nanovesicle comprises porphyrin phospholipid conjugates having cobalt chelated thereto.
9. A method of eliciting an immune response in an individual against streptococcal infection comprising administering to the individual an effective amount of a composition of claim 1 .
10. The method of claim 9 , wherein the elicited immune response is protective against an infection caused by S. pneumoniae.
11. The method of claim 10 , wherein the infection caused by S. pneumoniae is pneumonia.
12. The method of claim 9 , wherein the polypeptide in the composition is incorporated into a nanovesicle, wherein the nanovesicle comprises porphyrin phospholipid conjugates having cobalt chelated thereto.
13. The method of claim 9 , wherein the polypeptide in the composition is incorporated into a hybrid biological delivery vehicle.
14. The method of claim 9 , wherein the composition comprises an adjuvant.
15. The method of claim 12 , wherein the nanovesicle has an adjuvant incorporated therein.
16. The method of claim 13 , wherein the hybrid delivery vehicle has an adjuvant incorporated therein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/460,658 US20210393763A1 (en) | 2016-04-05 | 2021-08-30 | Novel pneumococcal vaccine formulations |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662318514P | 2016-04-05 | 2016-04-05 | |
PCT/US2017/026060 WO2017176833A1 (en) | 2016-04-05 | 2017-04-05 | Novel pneumococcal vaccine formulations |
US201816091032A | 2018-10-03 | 2018-10-03 | |
US17/460,658 US20210393763A1 (en) | 2016-04-05 | 2021-08-30 | Novel pneumococcal vaccine formulations |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/026060 Continuation WO2017176833A1 (en) | 2016-04-05 | 2017-04-05 | Novel pneumococcal vaccine formulations |
US16/091,032 Continuation US11103568B2 (en) | 2016-04-05 | 2017-04-05 | Pneumococcal vaccine formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210393763A1 true US20210393763A1 (en) | 2021-12-23 |
Family
ID=60001469
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/091,032 Active 2037-04-18 US11103568B2 (en) | 2016-04-05 | 2017-04-05 | Pneumococcal vaccine formulations |
US17/460,658 Abandoned US20210393763A1 (en) | 2016-04-05 | 2021-08-30 | Novel pneumococcal vaccine formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/091,032 Active 2037-04-18 US11103568B2 (en) | 2016-04-05 | 2017-04-05 | Pneumococcal vaccine formulations |
Country Status (5)
Country | Link |
---|---|
US (2) | US11103568B2 (en) |
EP (1) | EP3439693A4 (en) |
CA (1) | CA3020313A1 (en) |
MX (1) | MX2018012270A (en) |
WO (1) | WO2017176833A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018217882A1 (en) * | 2017-05-23 | 2018-11-29 | EMULATE, Inc. | Advanced pulmonary models |
EP3694490B1 (en) * | 2017-10-13 | 2024-03-20 | The Research Foundation for The State University of New York | Vaccine composition against streptococcus pneumoniae, use thereof for immunizing an individual against s. pneumoniae and method of preparation |
EP3962477A4 (en) * | 2019-04-30 | 2023-05-03 | The Research Foundation for The State University of New York | Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6699703B1 (en) * | 1997-07-02 | 2004-03-02 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
WO2016168817A1 (en) * | 2015-04-16 | 2016-10-20 | The Research Foundation For The State University Of New York | Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146486A1 (en) * | 2003-01-24 | 2004-07-29 | Juan Sun | Hybrid vector system for use as a vaccine |
KR20070122458A (en) * | 2005-02-11 | 2007-12-31 | 에이스 바이오사이언시즈 에이/에스 | Surface-located streptococcus pneumoniae polypeptides |
EP2251035A3 (en) * | 2007-04-12 | 2011-03-16 | Stichting Katholieke Universiteit, more particularly the Radboud University Nijmegen Medical Centre | New virulence factors of Streptococcus pneumoniae |
WO2009059054A2 (en) * | 2007-10-30 | 2009-05-07 | The Trustees Of The University Of Pennsylvania | Bacteria strains an d bacteriocin produced therefrom |
US20120100172A1 (en) | 2009-06-25 | 2012-04-26 | Michael Tal | Immunogenic streptococcus pneumoniae peptides and peptide-multimers |
WO2013040648A1 (en) * | 2011-09-23 | 2013-03-28 | Adelaide Research & Innovation Pty Ltd | Pneumococcal glpo immunogen |
-
2017
- 2017-04-05 WO PCT/US2017/026060 patent/WO2017176833A1/en active Application Filing
- 2017-04-05 US US16/091,032 patent/US11103568B2/en active Active
- 2017-04-05 EP EP17779708.1A patent/EP3439693A4/en active Pending
- 2017-04-05 MX MX2018012270A patent/MX2018012270A/en unknown
- 2017-04-05 CA CA3020313A patent/CA3020313A1/en not_active Abandoned
-
2021
- 2021-08-30 US US17/460,658 patent/US20210393763A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6699703B1 (en) * | 1997-07-02 | 2004-03-02 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
WO2016168817A1 (en) * | 2015-04-16 | 2016-10-20 | The Research Foundation For The State University Of New York | Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags |
Also Published As
Publication number | Publication date |
---|---|
MX2018012270A (en) | 2019-08-14 |
US11103568B2 (en) | 2021-08-31 |
WO2017176833A1 (en) | 2017-10-12 |
US20190307873A1 (en) | 2019-10-10 |
EP3439693A1 (en) | 2019-02-13 |
EP3439693A4 (en) | 2020-05-27 |
CA3020313A1 (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210393763A1 (en) | Novel pneumococcal vaccine formulations | |
US20210079047A1 (en) | Prevention, treatment and diagnosis of p.gingivalis infection | |
KR101716557B1 (en) | Neisseria meningitidis compositions and methods thereof | |
DK2866828T3 (en) | IMPROVED STREPTOCOCCUS SUIS VACCINES AND METHODS OF PRODUCING AND USING THEREOF | |
JP6435261B2 (en) | Stabilized protein for immunization against STAPHYLOCOCUSAUREUS | |
Nakahashi-Ouchida et al. | A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci | |
JP2009515831A (en) | Composition comprising a Yersinia pestis antigen | |
JP2012501959A (en) | Composition comprising Yersinia pestis antigen | |
JP2009500037A5 (en) | ||
JP2021035950A (en) | Mutant staphylococcal antigens | |
TWI583392B (en) | Treatment or prevention of infection | |
Norpi et al. | New modular platform based on multi-adjuvanted amphiphilic chitosan nanoparticles for efficient lipopeptide vaccine delivery against group A streptococcus | |
JP2015528457A (en) | Stabilized protein for immunization against STAPHYLOCOCUSAUREUS | |
US20120014993A1 (en) | Clostridium taeniosporum spores and spore appendages as surface display hosts, drug delivery devices, and nanobiotechnological structures | |
EP3694490B1 (en) | Vaccine composition against streptococcus pneumoniae, use thereof for immunizing an individual against s. pneumoniae and method of preparation | |
JP2015528456A (en) | Stabilized protein for immunization against STAPHYLOCOCUSAUREUS | |
KR20190082229A (en) | Vaccine constructs and their uses for Staphylococcus infection | |
JP2015532594A (en) | Stabilized protein for immunization against STAPHYLOCOCUSAUREUS | |
Nayerhoda | Development of Liposomal Encapsulation of Polysaccharides (Leps) Vaccine Design and Protection in Aged Hosts against Streptococcus pneumoniae Infections | |
JP7511188B2 (en) | Glycoconjugate vaccines | |
He et al. | Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus | |
US20230241208A1 (en) | Glyconjugate Vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PFEIFER, BLAINE;JONES, CHARLES;LOVELL, JONATHAN;SIGNING DATES FROM 20190208 TO 20190328;REEL/FRAME:057459/0407 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |